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 RESUMO 
Desordens musculoesqueléticas estão entre os acometimentos mais comuns a saúde 
humana com as fraturas ósseas se destacando como uma das mais debilitantes. Fraturas 
comprometem a qualidade de vida das pessoas e impõem significativa sobrecarga econômica 
a sociedade. O câncer ósseo, por sua vez, ocorre mais frequentemente em crianças e adultos 
jovens entre 5 e 20 anos de idade. Por ano cerca de 1000 novos casos de osteosarcoma (câncer 
ósseo) são diagnosticados só nos Estados Unidos. Por ano cerca de 1000 novos casos de 
osteosarcoma (câncer ósseo) são diagnosticados só nos Estados Unidos. Objetivando 
melhorar a qualidade do tratamento para essas condições nós alteramos a composição do 
vidro bioativo Bioglass®45S5 adicionando Dióxido de Nióbio (Nb2O5) ou Gálio (Ga). Nós 
buscamos dois diferentes objetivos principais: (1) aumentar a bioatividade do Bioglass®45S5 
por meio da adição do Nb2O5 o que alteraria a estrutura interna do vidro, aumentando sua 
taxa de dissolução e consequentemente a formação da camada de hidroxiapatita sobre sua 
superfície a fim de ser usado para a regeneração de grandes fraturas; (2) produzir vidros 
bioativos capazes de liberar Gálio localmente, de uma forma controlada, para que este atue na 
regeneração de defeitos ósseos pós- osteotomia enquanto mata células cancerígenas 
remanescentes no local da lesão. Para alcançar esses objetivos nós conduzimos duas séries 
diferentes de estudos que estão apresentados nessa tese em duas partes. A parte um descreve 
três investigações que mostram que a adição do Nb2O5 a rede do Bioglass®45S5 produziu 
um vidros biocompatíveis, não genotóxicos e com bioatividade aumentada estimulando maior 
formação de osso subperiostal e a diferenciação de Células Tronco Embrionárias humanas 
(CTEs) e Células Mesenquimais derivadas da medula óssea. Além disso, esses vidros sofram 
capaz de proporcionar a regeneração de um defeito ósseo de 5 mm de diâmetro na calvária de 
ratos em 8 semanas. A segunda parte dessa tese mostra um estudo no qual nós investigamos o 
potencial da incorporação de Gálio em vidros bioativos biodegradáveis projetados 
especificamente para aplicações em câncer ósseo. Nós observamos que adição de 3% de Gálio 
promoveu a morte de mais de 50% das células de osteosarcoma (SAOS2 cells) sem afetar os 
osteoblastos saudáveis. Os vidros bioativos contendo gálio fornecem uma entrega controlada 
e local de íons gálio no sítio da fratura e tem potencial considerável em aplicações clínicas 
para o tratamento de câncer ósseo. Nós acreditamos que através do desenvolvimento de novos 
biomateriais para substituição óssea nosso estudo irá contribuir para a redução da morbidade e 
melhorar o prognóstico de milhões de vítimas de fraturas. Além disso, o conhecimento gerado 
pelo presente trabalho vem a aumentar a compreensão acerca da interação entre substitutos 
 ósseos sintéticos e o tecido ósseo lesado, esclarecendo as respostas do corpo a presença de 
vidros bioativos contendo Nióbio ou Gálio. Assim, o presente estudo fomenta a literatura com 
informação relevante para prática clínica e futuras investigações.   
 
  
 ABSTRACT 
Musculoskeletal disorders are the most widespread human health issue with bone 
fractures standing among the most debilitating ones. Bone fractures compromises the quality 
of life of people and cause significant economic burden to society. On the other hand, bone 
cancer occurs most frequently in children and young adults between the age of 5 and 20 years, 
but may also grow in the elderly. Each year, about 1,000 new cases of osteosarcoma are 
diagnosed in the United States alone.Aiming to improve the quality of the treatment for these 
conditions we altered the composition of the Bioglass®45S5 adding Niobium Dioxide 
(Nb2O5) or Gallium (Ga). We targeted two different main goals: (1) increase the bioactivity of 
the Bioglass®45S5 by means of doping it with Nb2O5 which would alter the glass‟ internal 
structure, enhancing its dissolution rate and consequently the formation of a hydroxyapatite-
like layer on its surface in order to use it for the regeneration of large fractures; (2) to produce 
a Ga-doped bioactive glass that can  locally release gallium in a controlled manner to 
regenerate post-osteotomy defects whilst killing any remainder cancer cell. To meet these 
goals we conducted two different series of studies that are displayed in this thesis in two parts. 
Part one describes three investigations that show that the addition of Nb2O5 into 
Bioglass®45S5 produced biocompatible, non-genotoxic glasses which stimulated greater 
subperiosteal bone formation and the differentiation of Embryonic Stem Cells (ESCs) and 
bone marrow- derived Mesenchymal Stem Cells (BM-MSCs). Furthermore one composition 
of Nb-doped glass was able to regenerate a 5-mm size calvarial defect in rats after 8 weeks. 
The second part of this thesis shows a study in which we investigated the potential of 
incorporating gallium into bio-degradable bioactive glasses specifically targeted towards bone 
cancer applications. We observed that adding 3% of gallium killed more than 50% of the 
osteosarcoma cells (SAOS2) whilst it did not affect healthy human osteoblasts. The gallium 
doped bioactive glasses provide a localised controlled delivery of gallium ions at the surgical 
site of interest and has considerable potential clinical applications for bone cancer treatment. 
We believe that developing novel biomaterials for bone replacement our study will reduce the 
morbidity and to improve the prognostic of millions of victims of fractures. Nonetheless, the 
knowledge generated by the present work comes to improve the comprehension about the 
interaction between the synthetic bone substitutes and the injured bone tissue, clarifying the 
responses of the body in the presence of the Nb or Ga- doped bioactive glasses. Thus, the 
present study foments the literature with relevant information for clinic practise and further 
investigations. 
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INTRODUCTION 
Nb-doped bioactive glasses to treat bone fractures  
Throughout the history of humankind, several advancements in healthcare and 
infrastructure have provided humans with tools to slow down the process of natural 
selection. Nowadays, diseases that used to kill non-adapted individuals preventing their 
reproduction can be treated with a single pill
1
. As a result of this progress, the last 
century has witnessed a significant increase in life expectancy, whereby a human can be 
expected to live for 60-83 years on average
2
. The downside of these advancements was 
the emergence of a new category of diseases, known as „mismatch diseases‟. As the 
name suggests, these disorders are caused by a mismatch between our genetic code 
(which is still quite similar to that of the Palaeolithic men) and the environment we are 
now living in. Examples of these disorders include type 2 diabetes, stroke, 
atherosclerosis, cavities, osteoporosis, and some types of cancers
1
.  
Being one of the mismatch diseases that affect bones, osteoporosis is just the 
final step of a natural event that takes place in all human beings, called osteopenia. It is 
the process in which our bones progressively lose density due to the natural aging of our 
bone cells
3
. It did not seem to be a problem thousands of years ago because people did 
not use to live longer than 30-40 years. These days though, with many people reaching 
their seventies this progressive bone loss has been dramatically affecting the quality of 
life of millions of people around the world. Worldwide, osteoporosis is estimated to 
cause around 8.9 million fractures per year, which results in one fracture every 3 
seconds
4
. In fact, the International Osteoporosis Foundation (IOF) estimated that, 
worldwide, 1 in 3 women over age 50 will suffer osteoporotic fractures, as will 1 in 5 
men aged over 50
2
. 
The burden brought about by fractures is physical and psychological which 
consequently turns it into economical. In 2010 the total cost of fractures in the United 
Kingdom alone was about £4,3 billion
5
. Of course osteoporosis is not the only origin of 
fractures, but, it is certainly the one that is not likely to be reducing in the future decades 
as life expectancy and global population are only expected to increase.  
The continuing increase in the number of fractures has concerned governments 
and researchers igniting the search for new effective treatments that could accelerate 
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patient recovery and reduce the risk of morbidity and mortality following a fracture. 
These investigations culminated with several improvements in fracture healing and 
management
6
. An outstanding advancement was the development of inorganic materials 
that could be used to replace damaged bones and joints
7,8
. Due to the capacity of these 
materials to be implanted into the body without stimulating a significant immune 
reaction, they were named „Biomaterials‟9. The first generation of biomaterials was 
composed of low-reactive materials, such as some low-reactive metals and polymers. 
Their main characteristic was their compatibility with living cells, behaving as a nearly 
inert matter when inside the human body. Many „inert materials‟ were produced based 
on metals such as aluminum, zirconia and titanium, and are still used in orthopaedics for 
manufacturing prosthesis, plates, nails, screws, etc.  Polymers, on the other hand, have 
been used for drug delivery, extracellular matrix mimickers, and cartilage repair
8–11
.  
The problem with these nearly inert materials is the nature of their fixation with 
the living tissue. Basically, a nearly inert implant attaches to a living tissue 
morphologically. This means that they have indentations or grooves on their surface that 
are meant to be filled with new-forming bone
12
. The fulfilment of these grooves with 
new bone creates a morphological attachment that sticks both material and bone 
together. Nevertheless, micro movements that occur at the material-bone interface might 
compromise their fixation by stimulating bone resorption which consequently comes to 
reduce the stability of the implant. Moreover, metallic implants still show some level of 
rejection by the body that responds with some degree of encapsulation and a mild 
inflammatory response, which consequently also comes to cause instability
9
. These 
drawbacks limit the lifespan of these materials to 10 to 20 years
12
. With the increase in 
life expectancy, many patients began to outlive their implants. This constituted a serious 
problem for orthopaedic surgeons, as in order to replace a loose implant, the patient, 
often frail and elderly, would have to undergo further surgery.  
Interestingly, it was a war that ignited a revolution in the quality of bone 
implants. In 1969, a ceramic engineer named Larry Hench was attending a conference 
of the US Army Force to present his work on coatings for satellites. On his way to the 
conference he bumped into an army colonel. After an exciting talk explaining all the 
advantages of his satellite coatings, Hench was surprised by the following question, 
asked by the colonel: „If you can make materials that can resist solar radiation, can you 
create a material that is able to resist the human body?‟ This question instigated the 
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research that culminated with the development of the first bioactive material, the 
Bioglass® 45S5. It is a glass belonging to the system SiO2 – CaO – Na2O (45 wt% 
SiO2, 24.5 wt% CaO and 6 wt% P2O5)
8,13
.  
The main innovation brought about by this material was the fact that it was not 
only biocompatible; it was also formed bounds with hard and soft tissues
14
. 
Bioglass®45S5 when in contact with the body fluid, undergoes a series of inorganic 
reactions by means of ion exchange that result in the formation of a hydroxyapatite-like 
layer on its surface
8,13
. The formation of this layer is a crucial step for bioactivity once 
proteins and pluripotent cells attach to it and carry out a biological response. This 
response promotes osteogenic differentiation of the pluripotent cells and the formation 
and mineralization of a bone matrix
11
. This neo-formed mineralized bone matrix is so 
interconnected with the hydroxyapatite-like layer that Hench described this material-
bone interface as being even more resistant than both material and bone alone, which 
provided great stability for implants, solving the previous problems of instability and 
rejection
8
.  
By definition a bioactive material for use in bone replacement has to be 
biocompatible, osteoconductive (allow bone to grow onto its surface), osteostimulative 
(stimulate osteoblasts that are not in direct contact with its surface to proliferate and 
maturate), and osteoinductive (stimulate pluripotent cells to differentiate into 
osteoblasts)
11
. Bioglass® 45S5 was the first material to fulfil all of these requirements 
and started to be commercialized in the middle of the 1980‟s15. The original 
Bioglass®45S5 has been used in orthopaedics to repair bone defects of the jaw in more 
than one million patients. However, considering its potential, perhaps this figure is not 
as big as it should be. The composition still lacks bioactivity to repair large defects, so 
its use is limited to dental applications and the repair of facial bone fractures
15
.  
The biological properties of a material are directly related to its chemical 
composition. The great advantage of glasses is that one can easily manipulate their 
chemical structure to achieve different biological responses
10,11
. It was observed that the 
different ions that come from the dissolution of the glass, such as Si, Ca, and Na can 
influence cell response in different manners
16
. With that in mind, many researchers 
developed dozens of variations of the original Bioglass 45S5, some of which showed 
high bioactivity, e.g. 58S, S53P4, 70S30C
15,17
.  
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Recent works reported the ability of niobium ions to enhance differentiation and 
mineralization of osteogenic cells in in vitro assessment
18,19
. Niobium has been used in 
titanium alloys for endosseous implants, aiming to increase the biocompatibility, 
corrosion resistance and superior fatigue resistance
20
. Similar behaviors for phosphate 
bioactive glass were observed by adding Nb2O5
21,22
. Apparently, the most effective 
glass compositions for biomedical purpose are derived from silicate systems
17,23
. Niobo-
silicate bioglass compositions were first explored by our previous work
24
.  
In this study, we exhaustively investigated the structure of two series of bioglass 
(derived from 45S5 Bioglass) with varying niobium oxide contents using multinuclear 
29
Si, 
31
P, and 
23
Na solid-state MAS NMR and Raman spectroscopies combined with 
some physical properties of the glasses. The first series (I) was a substitution of P2O5 for 
Nb2O5, while the second series (II) was a substitution of SiO2 for Nb2O5, keeping the 
Na2O:CaO ratio fixed in both series. The results revealed that Nb2O5 participates of 
silicate network in different ways for both of the studied bioglass series. For Series I, 
Nb2O5 acts by breaking the Si-O-Si bonds to form structures such as -Si-O-Nb-O-Si- 
chains, while for the series II, it acts as crosslinker, forming crosslinks between the 
several oxygens of the silicate chains. The alterations observed in series I (mainly up to 
1.3% wt of N2O5), significantly increased the glass dissolution rate and magnitude, 
which is related to a greater bioactivity
24
.  
Even though Nb2O5-doped silicate glass appears to possess interesting bioactive 
properties, its effect over pluripotent cells and bone regeneration has not been 
investigated yet. In view of this, the objective of the investigations described in part one 
of this thesis was to evaluate the in vitro and in vivo effects of different compositions of 
these glasses on important issues for osteointegration of medical materials for bone 
replacement, such as, cytotoxicity, osteoinduction, osteoconduction, and 
osteostimulation. 
 
Ga-Doped bioactive glasses for bone cancer applications 
Bone cancer occurs most frequently in children and young adults between the 
age of 5 and 20 years, but may also grow in the elderly. Each year, about 1,000 new 
cases of osteosarcoma (one type of bone cancer) are diagnosed in the United States 
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alone. Approximately 450 of these are in children and teenagers
25
.  The mutations might 
be acquired during one‟s lifetime after repetitive exposure to carcinogenic agents such 
as radiation, as when patients that are undergoing repetitive radiotherapy to treat another 
prior cancer end up developing osteosarcoma. However, the majority of the cases seem 
to have a hereditary cause because other hereditary conditions that affect bones such as 
Li–Fraumeni syndrome (LFS), hereditary retinoblastoma (RB), Rothmund–Thomson 
syndrome (RTS), RAPADILINO syndrome (RAPA), Werner syndrome (WS), Bloom 
syndrome (BS), Diamond–Blackfan anemia (DBA), and Paget‟s disease of bone (PDB) 
seem to facilitate the development of bone tumors. The 5-year-survival rate of non-
metastatic disease is about 70% whereas metastatic disease is associated with survival 
rates of 15-30% 
25–27
.  
The standard treatment of osteosarcoma consists of surgical resection of the 
tumor, chemotherapy and, in some cases, radiotherapy. Nevertheless, despite advances 
in surgery and multi-agent chemotherapy, there has been no significant improvement in 
the survival of patients over the last four decades
25,27
. In order to improve the clinical 
outcome, safe and effective therapeutic materials are required. The minimum key 
requirements for an effective biomaterial targeted towards osteosarcoma therapy are (1) 
to successfully eradicate any residual tumour not excised during the surgery without 
being cytotoxic to the surrounding tissue and (2) to provide a suitable platform for the 
regeneration of new bone. A potential solution to this problem is to engineer materials 
capable of replacing damaged tissue whilst simultaneously preventing reoccurrence 
and/or metastases of tumours following surgery. The development of synthetic 
alternatives that help regenerate bone by acting as active temporary scaffolds has been 
nurturing considerable research activity. However there have been very few reports of 
synergistic scaffolds which can help manage cancer and simultaneously promote wound 
healing. Aiming to solve this problem we considered creating bioactive glasses that 
could be used for such purpose. The addition of Gallium (Ga) into the glass‟s network 
seems to be promising once Ga has successfully been used as a complementary agent in 
the treatment of some types of cancers
27,28
.  
Gallium is the second metal ion, after platinum, to be used in cancer treatment. 
Ga binds to the blood protein transferrin preventing its attachment to Fe
+3 27 
. The 
complex Ga-transferrin is internalized into cells by binding to transferrin receptors.  
Once inside the cells Ga is transferred to cellular ferritin, as is iron itself. It acts 
  
17 
 
 
inhibiting DNA synthesis and modifying the three-dimensional structure of the DNA, 
modulating protein synthesis, inhibiting H+ - dependent ATPase, among other 
functions. In sum, trivalent Ga acts as an antagonist to several divalent ions including 
Mg2+, Fe2+, Zn2+ and Ca2+, it promotes a decrease in cell proliferation and 
maturation and triggers cellular apoptosis
28
. It is well known that cancer cells possess 
more transferrin receptor than normal cells which highlights Gallium as a possible 
treatment for bone cancers.  
Based upon  its clinical efficacy, gallium nitrate (Ganite™) is used as a 
treatment for cancer-associated hypercalcaemia
28
. The recommended mode of 
administration for gallium nitrate is via a continuous intravenous infusion for 5–7 days. 
However, this treatment is very inconvenient since patients receive this drug either 
intravenously in hospital or as an outpatient via a pump device. A scaffold that can 
provide a site specific controlled delivery of gallium would therefore be highly 
advantageous. Gallium ions have previously been incorporated into phosphate based 
glasses to deliver a controlled antimicrobial effect
29,30
. Wren et al. and Towler et al. 
incorporated Ga into bioactive glasses for bone cement applications and for 
antimicrobial functionality
31
. More recently, Frachini et al. and Lusvardi et al. have 
incorporated gallium oxide into bioactive glasses for antimicrobial applications
32,33
. 
However there have been no studies undertaken on osteosarcoma cells. The 
investigation described in part two of this thesis aimed to verify the potential of 
incorporating gallium into bio-degradable bioactive glasses specifically targeted 
towards bone cancer applications. 
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 PART ONE:  DOPING BIOGLASS® WITH NIOBIUM DIOXIDE 
(Nb2O5) PROMOTES SUPERIOR BIOACTIVITY AND 
STIMULATES DIFFERENTIATION OF BOTH HUMAN 
EMBRIONIC STEM CELLS (hESCs) AND BONE-MARROW-
DERIVED MESENCHYMAL STEM CELLS 
Objectives of these studies: 
This set of experiments aimed to determine the effect of the addition of Nb2O5 
into Bioglass®45S5 over its structure and physicochemical properties as well as to 
verify the biocompatibility and the potential of these glasses to stimulate osteogenic 
differentiation of both Human Embryonic Stem Cells (hESCs) and Mesenchymal Stem 
Cells derived from the bone marrow (BM-MSCs). We also investigated whether Nb-
containing bioactive glass is able to stimulate bone regeneration in long and flat bones. 
The methods and results of these studies are described in the following scientific papers:     
Article 1: Comprehensive in vitro and in vivo studies of novel melt-derived nb-
substituted 45S5 bioglass reveal its enhanced bioactive properties for bone healing. 
(Accepted for publication by the journal Scientific Reports) 
Article 2: Systematic evaluation of the osteogenic capacity of novel melt-
derived nb-substituted 45S5 bioglass: in vitro and in vivo studies 
Article 3: Biocompatibility and osteostimulative properties of nb- containing 
bioactive glass: an experimental in vitro and in vivo study 
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ABSTRACT 
The present work presents and discusses the results of a comprehensive study on 
the bioactive properties of Nb-substituted silicate glass derived from 45S5 bioglass. In 
vitro and in vivo experiments were performed. We undertook three different types of in 
vitro analyses: (i) investigation of the kinetics of chemical reactivity and the bioactivity 
of Nb-substituted glass in simulated body fluid (SBF) by 
31
P MASNMR spectroscopy, 
(ii) determination of ionic leaching profiles in buffered solution by inductively coupled 
plasma optical emission spectrometry (ICP-OES), and (iii) assessment of the 
compatibility and osteogenic differentiation of human embryonic stem cells (hESCs) 
treated with dissolution products of different compositions of Nb-substituted glass. The 
results revealed that Nb-substituted glass is not toxic to hESCs. Moreover, adding up to 
1.3 mol% of Nb2O5 to 45S5 bioglass significantly enhanced its osteogenic capacity. For 
the in vivo experiments, trial glass rods were implanted into circular defects in rat tibia 
in order to evaluate their biocompatibility and bioactivity. Results showed all Nb-
containing glass was biocompatible and that the addition of 1.3 mol% of Nb2O5, 
replacing phosphorous, increases the osteostimulation of bioglass. Therefore, these 
results support the assertion that Nb-substituted glass is suitable for biomedical 
applications.  
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INTRODUCTION 
Fractures, bone tumours, periodontal diseases, and degenerative cartilage 
disorders disrupt daily activities of people. Therapeutic approaches to these pathologic 
conditions prompted the development of materials that could replace bone and joint 
tissues
1-3
. Many materials were produced based on metals, such as aluminium, zirconia 
and titanium, and were used in orthopaedics for manufacturing prosthesis, plates, nails, 
screws, and other such components. However, as these materials in general have a 
lifespan of around 10-20 years and human life expectancy has increased, these implants 
frequently deteriorate prior the patient‟s death6-8.  
At the beginning of the 1970s, the researcher Larry. L. Hench and his colleagues 
developed the first bioactive material, the 45S5 bioglass (Bioglass
®
). This biomaterial 
not only induced no inflammatory response in the body, but also formed strong bonds 
with bone and soft tissues, optimizing stability of the implant and extending its 
durability
8-10
. This material is a bioactive glass belonging to the system SiO2-CaO-
Na2O-P2O5 (46.1 mol% SiO2, 26.9 mol% CaO, 24.4 mol% Na2O, and 2.6 mol% P2O5) 
11
. The strong interface between biomaterial and tissue is established through chemical 
reactions that occur on the surface of the bioglass, concomitant with biological events 
leading to the formation of a nanocrystalline calcium phosphate hybrid composite 
permeated by biological molecules
9,10
.  
Several articles have been published, reviewing the literature discussing the 
effect of 45S5 bioglass composition on bioactivity, angiogenesis, osteostimulation, 
osteoconduction, and other important properties for bone regeneration
12-16
. As the 
chemical composition of glass dictates its effects on living tissues, many other 
variations of the original Bioglass
®
 have been manufactured and investigated for use as 
biomaterial; some of them showed high bioactivity, for example 58S, S53P4, and 
70S30C
2,17-21
.  
Furthermore, several types of transition metal-doped soda lime silica glass have 
been prepared, and their bioactivity has been evaluated for biomedical applications
22,23
. 
Among the various vitreous compositions investigated, glass containing niobium oxide 
have received special attention, since the presence of niobium species has been 
associated with improvements in bioactive and mechanical properties
24-28
. Moreover, 
recent works have reported the ability of niobium ions to enhance differentiation and 
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mineralization of osteogenic cells in vitro
26,27
. Metallic niobium has been used in 
titanium alloys for endosseous implants, aiming to increase the biocompatibility and 
corrosion resistance, with superior fatigue resistance
29
. Similar behaviour of phosphate 
bioactive glass was observed on adding Nb2O5
25,28
. It is noteworthy, however, that the 
Nb2O5 is an effective nucleating agent and generally leads to the development of glass-
ceramic in silica-poor compositions (inverted glass), such as 45S5
30
.  
In our previous study, the structures of two series of bioglass (derived from 45S5 
Bioglass
®
 composition) with varying niobium oxide contents were exhaustively 
investigated by multinuclear 
29
Si, 
31
P, and 
23
Na solid-state MAS NMR and Raman 
spectroscopy, and some physical properties of the glass were also studied
31
. The 
structural investigation of bioglass resulting from the substitution of P2O5 by Nb2O5 
revealed that Nb2O5 participates in the silicate network by breaking the Si-O-Si bonds to 
form structures, such as -Si-O-Nb-O-Si- chains. These alterations significantly changed 
the glass dissolution rate and magnitude, which is of interest for understanding its 
higher bioactivity
31,32
.  
Even though Nb-substituted silicate glass appears to possess interesting 
bioactive properties, its effect over pluripotent cells and bone regeneration has not been 
investigated till date. In view of this, the objective of this study was to evaluate the in 
vitro and in vivo effects of different compositions of Nb-substituted bioglass on 
properties, namely, cytotoxicity, osteoinduction, osteoconduction, and osteostimulation, 
that are essential for osteointegration of medical materials for bone replacement. The in 
vitro approach consisted of treating human embryonic stem cells (hESCs) with the 
dissolution products from the glass and verifying cell viability and osteogenic 
differentiation. For the in vivo assay, glass rods were implanted into circular defects in 
rat tibia and bone formation was quantified. In addition, the leaching profile of Si, Ca, 
Na, P, and Nb species from the bioglass, and the kinetics of structural transformations 
of different compositions of Nb-substituted silicate glass were investigated. 
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Results and Discussion 
Dissolution studies. The leaching rate of Na, Ca, Si, and P ions from bioglass in 
the earliest stages of the bioreactivity is of utmost importance since the results of the 
leaching processes will control the subsequent biomineralization. To examine leaching 
rates, two promising compositions of Nb2O5-containing bioactive glass were studied. 
The 45S5 bioglass composition is also presented for the purpose of comparison. The 
nomenclature and chemical composition of all samples studied in this work are shown 
in Table 1. 
Table 1 - Glass compositions of BG45S5 and Nb-substituted 45S5 bioglass. 
Glass 
 
SiO2 CaO           Na2O P2O5         Nb2O5 
BG45S5 46,1 26,9 24,4 2,6 - 
BGPN2.6 46,1 26,9 24,4 - 2,6 
BGPN1.3 46,1 26,9 24,4 1,3 1,3 
 
The effect of Nb2O5-content on the glass solubility was studied by time-
dependence of species release from bioglass particles dispersed in 50.69 mM HEPES 
buffered solution (pH = 7.4). The leaching curves for Na, Ca, Si, P (Figure 1) and Nb 
(Figure 2) species were determined by using inductively coupled plasma optical 
emission spectrometry (ICP-OES). 
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Figure 1. ICP data: ion release vs. time in 50.69 mM HEPES solution at pH 7.40 
for BG45S5 and Nb- substituted bioactive glass. The data displayed in (a), (b), (c) and 
(d) are related to leached Na, Ca, Si, and P species from glass derived from substitution 
of P2O5 for Nb2O5. 
We found that the initial elemental concentrations of sodium, calcium, silicon, 
and phosphorus, up to about 120 min for all compositions, are a linear function of the 
square root of time, which indicates a diffusion-controlled process (Supplementary 
Information - Figure SI3 a-d)
10. The shape of the curves is consistent with Hench‟s 
mechanism, which describes all events on bioglass surface in contact with body fluid in 
five steps: (i) rapid exchange of Na
+
/Ca
2+
 from glass network with H3O
+
 from solution, 
(ii) loss of soluble silica/ formation of silanol groups at the glass solution interface, (iii) 
condensation and repolymerization of a SiO2-rich layer, (iv) growth of the amorphous 
CaO-P2O5-rich film by incorporation of soluble calcium and phosphates from solution, 
(v) crystallization of the amorphous CaO-P2O5 film by incorporation of OH
-
 and CO3
2-
 
anions from solution 
5,6,9,33
. 
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The leaching profiles of network modifier ions, Na
+
 and Ca
+
, for BG45S5 and 
Nb2O5-substituted bioglass showed an abrupt increase, reaching a maximum 
concentration value for these species at around 2 hours and remaining constant for 
longer times (Figure 1a-b). The release curves showed that the amount and rate at 
which Na and Ca ions are leached from the glass networks were similar to each other, in 
particular, within the first hours after dipping. This result is of extreme importance 
because it shows that the replacement of P2O5 by the Nb2O5 in the 45S5 composition 
did not alter the onset of the cascade of events, which includes ion exchange between 
Na
+
 and Ca
2+
 ions and H3O
+
, as described by the Hench mechanism for 
biomineralization
9,33,34
. In addition, recognizing that sodium niobate and/or calcium 
niobate are highly water insoluble species close to the neutral pH, these results 
corroborate with those previously reported on structural data for these glassy 
compositions
31
, suggesting that niobium (NbO6) would be behaving as a network 
former by establishing chemical bonds with silicon tetrahedral (Si-O-Nb-O-Si) in the 
glass backbone (chain of alternating Si and O atoms). 
Conversely, the leaching curves for the species of silicon and phosphorus 
showed peculiar behaviours for each bioglass composition (Figure 1c-d). The amounts 
of soluble silicon species determined after the first hour of immersion were similar, 
except for the BGPN2.6 sample, which exhibited a reduced concentration of silicon. 
This result indicates the presence of Si-O-Nb bonds, where the NbO6 octahedra replaces 
part of the SiO2 tetrahedra in the glass network. Evidently, an increase in niobium 
content in the composition must result in a greater number of Nb-O-Si bonds, so that 
such structures may act as traps for the silicon species in the glass matrix, preventing 
and delaying their leaching. The release profile of phosphorus suggests a maximum 
concentration (approximately the solubility limit), from which there is a dramatic 
reduction, possibly associated with the removal of some of the soluble phosphate 
species to form the calcium phosphate layer on the bioglass surface (Figure 1d). 
Although the rate at which species of phosphorus are released into solution is similar to 
BG45S5 and BGPN1.3 samples, the removal of phosphorus from solution is slower for 
the BGPN1.3, which can be attributed to its lower P2O5 concentration (phosphorus 
concentration was not high enough to reach the limit solubility of calcium phosphate). 
As expected, no appreciable amount of phosphate species was observed for BGPN2.6.  
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The leaching curves for the species of niobium exhibit similar profiles to those 
observed for phosphorus species (Figure 2). 
 
Figure 2. ICP data: Nb ion release vs. time in 50.69 mM HEPES solution at pH 
7.40 for BG45S5 and Nb-substituted bioactive glass. The amounts of niobium 
determined by ICP-OES is consistent with the niobium content in each sample, i.e. 
BGPN2.6 exhibits a higher peak of niobium concentration compared to the BGPN1.3 
bioglass. As expected, no niobium was detected for BG45S5. 
At early soaking times, it is possible to observe an abrupt increase in the 
niobium concentration in the medium, reaching a maximum value, followed by a 
dramatic reduction of concentration value. This initial burst can be credited for the 
leaching of niobium species near surface and/or release of isolated NbO6 units isolated 
niobium octahedral in the vitreous matrix, which are more labile since their release does 
not require extra energy to break bonds. The maximum niobium species concentration 
determined for samples BGPN1.3 and BGPN2.6 was 0.4 ppm after 30s and 0.9 ppm 
after 1 minute, respectively. The drastic decrease in niobium content observed for 
samples BGPN1.3 and BGPN2.6 is closely related to the very low solubility of niobium 
species at pH 7.4 in aqueous medium. The presence of a second peak of Nb 
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concentration was observed for the BGPN1.3 and BGPN2.6 bioglass of 0.4 ppm after 5 
minutes and 0.5 ppm after 120 minutes, respectively. This second event is directly 
related to the leaching of isolated niobium species in the bulk and/or Nb species that 
were more firmly trapped in the vitreous network. Again, the abrupt decrease in 
niobium concentration is due to the fact that the product solubility is small for niobium 
species. In fact, the concentration of niobium after each release peak tends to go to zero, 
confirming that the residence time of the Nb species in the solution body is short. 
Consequently, almost all niobium, if not all, may be retained in aggregates in the 
solution (removed during the filtration step) or in silica gel formed at the 
bioglass/solution interface. 
Generally, it is common to use chelating agents such as citrates and oxalates to 
increase the solubility of niobium species
35,36
. It is noteworthy that all the studies of 
leaching presented in this report were carried out using a medium containing HEPES, 
which is an often-used agent in studies, among several other reasons because it does not 
chelate with metals. Obata et al
27
 investigated a glass series belonging to 60CaO-
30P2O5-(10-x)Na2O-xNb2O5 - system (mol%, x = 0-10) and quantified the content of 
niobium in the leachate by ICP-OES after a few hours of immersion. However, in this 
study, the dissolution of the glass was carried out in a complex culture medium 
(minimal medium culture + bovine serum) containing various chelating ligands, which 
may explain the presence of niobium in the solution. It is also worth noting that these 
phosphate glasses studied by Obata and co-workers can dissolve completely in aqueous 
solution giving ionic species, which may form precipitates upon reaching the maximum 
solubility (solubility product constant - Ksp). Moreover, another important point 
deserving attention in the work of Obata is that the culture medium has not apparently 
been filtered, consequently, the undissolved vitreous particles and the possibly formed 
ionic-molecular agglomerates, both containing niobium, remain in the medium. Hence, 
not only the niobium species chelated in the medium, but also those present in the glass 
particles or aggregates are released into the solution during the oxidation step of the 
organic material (commonly under acidic conditions) required for ICP-OES analysis 
were quantified
27
. Thus, the low solubility of the species of niobium in solution together 
with the filtration step using membranes of 0.22 μm, and the absence of chelating agents 
in the present study suggests that the Si-O-Nb bond undergoes hydrolysis, but only 
small amount of niobium goes into the solution, while the leached niobium tends to 
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form complex structures (niobium-silica gel layer), which is retained on the glass 
surface. 
Apatite layer formation ability by 
31
P MAS NMR spectroscopy. The 
development of an apatite layer on the bioglass surface in the physiological environment 
(even under simulated conditions) is a common feature among all the bioactive vitreous 
compositions described in the literature
9,10,18,37
. Therefore, the time required for this 
layer to be established has been an initial parameter for assessing and ranking the 
different vitreous compositions in the bioactivity domain, since apatite is a cell-friendly 
environment
10,20
. In contrast to other analysis methods, MAS NMR spectroscopy is a 
powerful, univocal and sensitive tool for studying changes in the chemical environment 
of phosphorus, capable of identifying subtle changes in local structural arrangement of 
phosphorus even for early soaking times. The partial dissolution and apatite formation 
on the bioglass surface in simulated body fluid (SBF) has been verified by 
31
P MAS 
NMR (Figure 3 (a-c)). 
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Figure 3. 31P MAS-NMR spectra for the different glass compositions, recorded 
at a magnetic field strength of 9.4 T and a spinning speed of 10 kHz: (a) BG45S5, (b) 
BGPN1.3, and (c) BGPN2.6. The chemical environmental for 31P shifts progressively 
evolves to lower values of δ, reaching a peak position similar to the 31P spectrum 
observed in the hydroxyapatite control. The absence of phosphorus in BGPN2.6 did not 
prevent the calcium phosphate layer formation on its surface. 
The 
31
P MAS NMR spectrum of BG45S5 consists of one broad resonance with 
linewidth of 7.9 ppm and peak maximum at 9.0 ppm assigned to isolated 
orthophosphate units, which coordinate modifier cations (Na
+
 and Ca
2+
), subtracting 
them from the silicate network
31,32
. The 
31
P resonance spectra for the glass compositions 
containing Nb2O5 illustrate a similar spectrum to BG45S5 with one broad resonance and 
asymmetric peak with a chemical shift ranging from 18 to -3 ppm with an approximate 
linewidth of 8 ppm.  
31
P MAS NMR peak positions and full width half maximums (FWHM) for 
BG45S5 and Nb-substituted glass, unreacted and after 3, 12, and 24 hours of immersion 
in SBF are listed Table 2. 
31
P MAS NMR spectrum of commercial hydroxyapatite was 
added as a reference for the phase of calcium phosphate formed. 
Table 2 - 
31
P MAS NMR peak positions and full width half maxima (FWHM) 
for BG45S5, Nb-substituted 45S5 bioglass and commercial hydroxyapatite. 
 
In general, 
31
P MAS NMR spectra for all glass exhibit the same trends, which 
can be summarised by the chemical shift to lower frequencies and a decrease in FWHM 
values. Such spectral changes are intimately related to partial degradation of glass and 
precipitation of amorphous calcium phosphate and its progressive crystallization
32
.  
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31
P MAS NMR spectra for BG45S5 (Figure 3a) and BGPN1.3 (Figure 3b) after 
3 hours of incubation in SBF showed a main peak at ~4 ppm with slight asymmetry on 
the left-hand side of the peak owing to the residual glass fraction. This subtle spectral 
feature was not observed for BGPN2.6 (Figure 3c), which exhibited a single and 
symmetrical peak at 3.6 ppm, confirming that the presence of P2O5 in the glass bulk is 
not mandatory for precipitation of calcium phosphate layer. Although subtle, the 
changes observed in the spectra in the range of 3-24 hours are related mainly to the 
gradual increase in the crystallinity of calcium phosphate (increase of long-range order). 
The 
31
P MAS NMR spectra after 24 hours in SBF for all the glass compositions show 
chemical shifts and bandwidths similar to those observed for commercial 
hydroxyapatite (top spectrum in Figure 3c). These results indicate that glass containing 
niobium leads to the formation of a calcium phosphate with a higher degree of 
crystallinity compared to BG45S5, with similar  
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soaking time in SBF. In fact, it has been reported that Nb-OH groups in the amorphous 
phase of sol-gel-derived niobium oxide gels are very effective for apatite nucleation, 
which is a friendly environment for cells
38
. 
Biocompatibility assessment. The first step when developing a new biomaterial 
to be used for tissue replacement is to ensure that it cannot represent a risk when 
implanted into the body. Therefore, we carried out in vitro and in vivo experiments to 
test the biocompatibility of Nb-containing glass. In the in vitro approach we treated 
human embryonic stem cells (hESCs), CCTL12, with the dissolution products of Nb-
containing glass (BGPN1.3 and BGPN2.6) and the control glass (BG45S5) for 14 days 
and performed a resazurin assay. This assay revealed that none of the glass 
compositions were cytotoxic (Figure 4).  
 
Figure 4. Relative fluorescence of hESCs stained with 5 µM of resazurin after 
14 days of treatment with different culture media. There was no significant difference 
between the groups, which shows that none of the media were cytotoxic for this cell 
line. This study was carried out only for the BG45S5 and BGPN1.3 samples. cHES: 
conditioned human embryonic stem cells medium. 
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Both, BG45S5 and BGPN1.3 glass showed similar fluorescence relative to that 
of the control group (cHES medium) after 14 days of treatment (P > 0.05). This result 
corroborates with those from some other reports
24,27,39
 that have studied the 
cytocompatibility of bioactive glass containing niobium; these studies concluded that 
the addition of this metal does not impair the compatibility of the biomaterial. One of 
these reports showed that when osteoblast-like cells are in direct contact with the 
surface of calcium phosphate invert glasses (PIGs) containing Nb2O5 they attach and 
spread after 6 hours on all different concentrations of soluble niobium species
27
. The 
same authors performed experiments with dissolution products of niobium-doped PIGs 
and revealed that they are not harmful for osteoblast-like cells (MC3T3-E1), and instead 
they stimulated some positive biological responses
27
. 
Similar results were found by another study using a different cell line and a 
different formulation
26
. In this study, human mesenchymal stem cells (hMSCs) were 
cultured on niobium-doped fluorapatite glass-ceramics, and the results showed that after 
3 hours, the hMSCs attached on niobium glass as well as they did on the control 
surface; the report also shows the scanning electron microscopy (SEM) micrographs of 
cells attached to the glass surface after 2-4 days
26
.  
Testing cytocompatibility is not enough to ensure the safety of implants. 
Inorganic material may intoxicate some high-metabolic-rate organs that participate in 
the metabolism and excretion of the material, for example the liver and kidneys, which 
may lead to morphological alterations in these organs. Because of that, we calculated 
the relative weights of the livers and kidneys of rats that had undergone implantation of 
glass rods at circular defects in their tibia, and compared the mean values with a control 
group of rats. We observed no difference between the groups neither after 14 nor 28 
post-operative days, proving that no alterations in these organs were caused by the 
presence of the inorganic implants (Table 3).  
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Table 3 - Relative weight of liver and kidneys of rats treated with different 
bioactive glasses for 14 and 28 days. 
Time  Groups  Liver (g)  Kidneys (g)  Body Weight (g) 
14 days 
 Control  11.4 ± 0.2  5.17 ± 0.07  366.0 
 BG45S5  11.4 ± 0.2  5.28 ± 0.06  381.0 
 BGPN1.3  11.4 ± 0.1  5.10 ± 0.09  376.0 
 BGPN2.6  11.2 ± 0.1  5.22 ± 0.07  373.0 
 Sham  11. 5 ± 0.2  5.29 ± 0.08  387.0 
28 days 
 Control  10.8 ± 0.1  5.0 ± 0.1  474.0 
 BG45S5  10.8 ± 0.2  5.00 ± 0.07  466.0 
 BGPN1.3  10.74 ± 0.08  4.99 ± 0.05  434.0 
 BGPN2.6  10.9 ± 0.1  5.05 ± 0.07  421.0 
 Sham  10.6 ± 0.2  5.02 ± 0.04  443.0 
Average values of 6 animals. represented by mean ± SEM. Considering p<0.05 
no significant difference was detected. One-way ANOVA followed by Student 
Newman-Keuls test. Sham = no bone defect was created. 
Taken together, these results suggest that regardless of the biological model and 
material formulation used, Nb-substituted bioglass is biocompatible, and such bioglass 
have proved to be excellent candidates for biomedical applications. 
Osteogenic potential of Nb-containing bioglass. Several studies have shown 
that by transplanting adequate numbers of competent osteoprogenitor cells on 
biomaterial scaffolds, cell-based bone tissue engineering strategies may promote 
functional reconstruction of skeletal defects
40-42
. We chose to work with human 
embryonic stem cells (hESCs) because we believe these cells show some important 
advantages compared to other more commonly used multipotent cell types like 
mesenchymal stem cells (MSCs). We understand that MSCs may represent a reliable 
source of multipotent stem cells for bone cell transplantation. However, the fact that the 
numbers of adult MSCs are limited, and decline with age
43
, and because they are present 
at different stages of differentiation at the time of harvest
44
, their use is not without 
problems. Human ESCs, on the other hand, possess unlimited growth and 
differentiation potential, accessibility, and do not require a donor site
45
, facilitating the 
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acquisition of a large amount of cells to be used with biomaterial scaffolds for bone 
regeneration.  
The capacity of niobium to stimulate osteogenic differentiation of hESCs was 
tested by the analysis of matrix mineralization, carried out after 21 days of treatment. 
This assay revealed the formation of large calcified nodules on the cells treated with 
BGPN1.3, which suggests cells differentiated into osteoblasts that formed a mineralized 
bone matrix. These nodules were larger than those observed in the cells treated with 
BG45S5 (Figure 5). 
 
Figure 5. Micro and macrographs of calcium deposits within and around hESCs 
stained with alizarin red (1%) after 21 days of treatment with different media. The four 
large squares show micrographs (100× magnification) in which the red aggregates 
(indicated by the arrows) are calcium deposits. The small squares show the photographs 
taken of each well. Cells treated with osteogenic medium (OS) showed a fully 
mineralized matrix which means that most hESCs were in a late stage of differentiation 
to osteoblasts. Those cells treated with BGPN1.3 showed a greater degree of matrix 
mineralization than those treated either with BG45S5 or DMEM/F12. This study was 
carried out only for the BG45S5 and BGPN1.3 samples. 
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The products leached from bioactive glass seem to stimulate stem cells to 
proliferate and differentiate to osteoblasts by activating different intracellular 
pathways
6,8,46
. Lopes et al. observed that the incorporation of up to 1.3% of Nb2O5 by 
replacing the P2O5 in a SiO2-Na2O-CaO-P2O5-Nb2O5 system imposed significant 
structural changes on the glass, altering its solubility and the rate and magnitude of the 
Na, Ca, Si and P species leaching from the glass network, compared to niobium-free 
bioglass
31
. 
Although a receptor for Si has not been identified yet, this ion has been shown to 
be one of the main components of bioglass that is responsible for osteogenic 
stimulation
6,47,48
. As a component of silicic acid [Si(OH)4], silicon has been shown to 
stimulate osteoblasts to produce collagen I, which is the main component of the 
extracellular bone matrix
46
. On the other hand, the receptors and intracellular pathways 
activated by Ca
+2
 in osteoblasts as well as its indirect roles in the bone formation 
process are very well described
46,49
. 
It is well known that calcium possesses both structural and signalling roles in 
regulating bone homeostasis
46,50-52
. Structurally, hypercalcemia is required to produce 
mineralized bone as it is combined with PO4
-3
, precipitating as calcium phosphate, 
which constitutes the inorganic phase of the bone matrix. Furthermore, Ca has an 
important role in regulating bone homeostasis by signalling pathways in bone-forming 
osteoblasts
46,50,52,53
. It has been reported that this ionic signalling enhances proliferation 
of stem and mature bone cells through binding to a G-protein, coupled to an 
extracellular calcium sensing receptor, in a process dependent on nitric oxide (NO) 
production. Downstream in this signalling, the P13K/Akt pathway is activated, ensuring 
the surveillance of the osteoblasts
46
.  
Niobium species seem to have a direct effect on cells. This fact was 
demonstrated by Obata et al. by treating mouse osteoblast-like cells (MC3T3-E1 cell) 
with media containing different concentrations of niobium ions (between 1  10-8 to 
1  10-5 M)27. Their results showed that, independent of the concentration, niobium did 
not compromise cell proliferation. Besides this observation, they noted that the ions 
stimulated a significantly higher alkaline phosphatase activity (APA) in a dose-
dependent manner, indicating cell differentiation after 14 days, even in a medium 
devoid of an osteogenic supplement. When osteogenic media was conditioned with the 
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same ion concentrations, a significant dose-dependent increase was observed in calcium 
deposition compared to that in the osteogenic medium without niobium ions, suggesting 
that the niobium ions stimulated greater calcium deposition, which is an indicator of cell 
maturation. Although we have not studied specific intracellular pathways, we suggest 
that the greater osteogenic differentiation stimulated by Nb-substituted bioglass 
observed in our study may have been caused by the presence of niobium species, since 
the amount of the other bioactive ionic species (based on Si, Ca, Na, P) were similar 
between the groups. This suggestion corroborates with the results of the aforementioned 
study
27
. 
It is worth mentioning that ICP-OES analysis allowed quantification of the 
ionized Na, Ca, Si, P, and Nb species released from the glass, but the results do not 
provide any information on their bioavailability or molecular structure. The dissolution 
products generated are likely to be in the form of compounds of the elemental 
constituents of the glass rather than individual ions. Thus, drawing conclusions based 
only on ion concentration may seem an oversimplification. Obviously, in more complex 
media, such as culture media or corporeal fluid, the presence of chelating molecules and 
the ionic strength of the medium may alter the release profile and bioavailability of 
these species. In order to determine the levels of each element and its bioavailability, the 
quantification of the leached species from the vitreous matrix, concomitant with 
molecular speciation studies in a complex, more realistic, media, would be an ideal 
study, but is a technically challenging experiment. Further studies should focus on 
determining specifically which compounds are released, which intracellular pathways 
take part in the osteogenic process, and which genes are regulated by the presence of the 
bioglass-derived compounds.  
Bone formation stimulated by Nb-containing bioactive glass. In vivo 
experiments were performed in order to analyse the bioactive properties of 
osteostimulation and osteoconductivity of different Nb-containing glass compositions. 
Glass rods were implanted into the tibia in rats to test their biological properties by 
quantifying the newly formed subperiosteal bone and the thickness of the bone layer 
formed over and near the surface of the rod.  
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Comparison of subperiosteal bone area in the rod group tibia and those in a 
control group showed no significant difference after 14 days of implantation [F (3, 16) = 
1.881, p= 0.174)] (Figures 6 and 7).  
 
Figure 6. Micrographs of transversal histological sections of rat tibia tissues 
stained with Haematoxylin & Eosin after 14 days of implantation with different glass 
compositions. All groups showed similar amount of subperiosteal bone formation 
[F(3.16) =1.881, p= 0.174, ω= 0.34]. 
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However, after 28 days, BGPN1.3 induced a significant effect on bone 
formation [F (3, 16) = 6.375, p= 0.005]. The tibia bones in which BGPN1.3 was 
implanted showed greater subperiostal bone area (51513.88 ± 2050.08 µ
2
) than the 
control (BG45S5) (46537.19 ± 2050.08 µ
2
) (Figures 7 and 8). 
 
Figure 7. Micrographs of transversal histological sections of rat tibia tissues 
stained with Haematoxylin & Eosin after 28 days of implantation of different glass 
compositions. The groups differed regarding newly-formed bone area [F(3.16) = 6.375, 
p=0.005, ω= 0.67]. The group BGPN1.3 showed greater bone area (51513,88 ± 1265,13 
μm2) than BG45S5 (46537.19 ± 2050.08 μm2) (p = 0.011) and BGSN1(40614.49 ± 
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3360.57 μm2) (p = 0.004) as can be seen on the micrographs in the right column (200× 
magnification). 
 
Figure 8. Quantitative analysis of the area of newly-formed subperiosteal bone 
in rats treated with the different bioactive glass. After 28 days the group treated with 
BGPN1.3 showed significantly greater bone formation than the control group (treated 
with BG45S5). All data are displayed as mean and SEM. For all comparisons p < 0.005 
was considered. 
Moreover, the presence of niobium did not alter the osteoconductivity of the 
glass, stimulating the formation of a bone layer over its surface, displaying thicknesses 
similar to the control group [F (3,16) = 0.423, p= 0.739] (Figure 9). 
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Figure 9. Quantitative analysis of the area of newly-formed subperiosteal bone 
in rats treated with the different bioactive glass. After 28 days the group treated with 
BGPN1.3 showed significantly greater bone formation than the control group (treated 
with BG45S5). All data are displayed as mean and SEM. For all comparisons p < 0.005 
was considered. 
We believe the greater bone formation stimulated by Nb-containing glass was 
caused by the release of Nb species that could have acted in two ways: (a) directly 
acting over cells by the mechanism explained by the mechanism explained previously in 
the in vitro section of this work  and (b) by acting as nucleation agent, forming 
microscopic needle-shaped crystals on the surface of the glass
54
. This confers a 
microscopic complexity to the glass surface, which is thought to be critical for in vivo 
contact osteogenesis to occur
26
. It is stated that a micro or nanoscopic complexity 
allows greater protein, mainly fibrin, adsorption, and that platelets aggregate on this 
fibrin net and secrete cytokines that recruit osteogenic cells to the implant site
55
. These 
cells differentiate in osteoblasts and produce a collagen-rich matrix which is further 
calcified, and newly formed bone is strongly anchored to the surface of the material 
with an interfacial bond strength equal to or greater than the natural bone
9
. This 
mechanism explains the osteoconductivity displayed by all glass evaluated in the 
present study.  
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We believe that the greater subperiosteal bone formation of the different Nb 
glass formulations was caused by a direct effect of the leached ionic products (Si, Ca, 
Na, and P) on the periosteal osteogenic cells, possibly throughout the mechanisms 
previously discussed in the section “Osteogenic potential of Nb-containing bioglass” of 
this paper. In short, the leached ionic products may ultimately  have caused the 
upregulation of the expression of important genes for cellular differentiation and 
maturation. For example, extracellular calcium ions are known to increase the 
upregulation of IGF-II, one of the main growth factors for bone formation
52,53
. 
CONCLUSION 
To summarise, our results showed that the addition of Nb2O5, replacing P2O5, 
within glass networks increased bioactivity of the glass. All glass compositions derived 
from Bioglass
®
 tested in the present study exhibited similar release profile for Si, Na 
and Ca species compared to BG45S5, in addition to the release of niobium species by 
the compositions of Nb-containing glass. The release of niobium species may have been 
responsible for the observed enhanced osteogenic and osteostimulative properties.  
Solid state 
31
P MAS NMR proved to be a very sensitive technique to elucidate 
the in vitro chemical reactivity and bioactivity of niobium bioactive glass. 
31
P MAS 
NMR showed that glass containing lower quantities of Nb2O5 (BGPN1.3) exhibited 
enhanced early glass apatite formation, whereas for glass compositions containing 
higher amount of Nb2O5 (BGPN2.6) the opposite effect was observed. 
Nb-substituted silicate glass is not toxic to hESCs and does not cause any 
problems for liver and kidneys of rats, proving their biocompatibility. The results 
suggested that hESCs differentiated toward osteoblast lineage after treatment with the 
dissolution products of Nb-containing glass, revealing the osteogenic capacity of 
niobium. In vivo experiments showed that after 28 days, Nb-containing bioglass induced 
a significant effect on bone formation. Based upon these results, we suggest Nb-
substituted silicate glass may be an interesting alternative for biomedical applications.  
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MATERIALS AND METHODS 
Preparation of Bioglass Samples. Details on the preparation of bioglass 
samples can be found in our previous publications
11,31,33,34
. High purity SiO2, Na2CO3, 
CaCO3, P2O5 powders (>99.9%), were weighed to obtain the glass compositions 
depicted in Table 1. All precursor reagents were purchased from Sigma-Aldrich (St. 
Louis, MO, USA), except for niobium oxide (Nb2O5, optical grade, >99.5%), which was 
donated by the CBMM (Companhia Brasileira de Metaluria e Mineração, Araxá, 
Minas Gerais, Brazil). Thirty-gram batches were melted in a platinum crucible at 1400 
°C in air for 3 hours using a furnace (Lindberg/Blue M 1700 °C, Thermo Electron 
Corporation, Asheville, NC, USA). At the end of the refining process, the melts were 
quenched directly into cold water (frit cast), collected in a sieve, and dried to constant 
weight at 120 °C overnight. The different types of glass were then ground using an 
agate mortar and pestle, and sieved to separate fine (< 38 µm) and coarse (> 53 µm) 
particles. All experiments described in this work were carried out using glass particles 
size between 38-53 µm, excepting the in vivo studies for which cylindrical rods with 4 
mm length x 2 mm diameter were used. These samples were prepared by casting 
method in a graphite mould (Figure SI2). Glass rods were annealed at 50 °C below the 
glass transition temperature (Tg) for 12 h and slowly cooled to room temperature to 
release the thermal stress associated with the quenching process. 
 
Ion Leaching Experiments by ICP-OES. The ionic leaching patterns of the 
bioactive glass were determined by inductively coupled plasma optical emission 
spectrometry (ICP-OES). In this experiment, 300 mg of bioglass particles were 
dispersed in a beaker with 200 mL of buffer solution and maintained under continuous 
stirring (stirring rate of 75 rpm), at room temperature. The solution was buffered at pH 
7.40 by using 50.69 mM HEPES (2-(4-(2-hydroxyethyl)piperazin-1-yl)ethanesulfonic 
acid) and 1 mM NaOH, both purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Prior to the addition of the glass particles, 50.69 mM HEPES solution was passed 
through a 0.22 μm Millipore® filter to remove eventual aggregates or contaminants. 
During the leaching experiment, the beaker was kept sealed with parafilm in order to 
avoid any loss of liquid by evaporation, preventing changes in the ratio of glass/HEPES 
in the solution. After 3, 6, 12, 24 and 48 hours, 10 mL of solution was removed with a 
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syringe. Since the powder suspension was well dispersed and homogenous, the sample 
removal did not alter the solution concentration. For this reason, the solution was not 
refilled after collecting samples, resulting in a final volume of the solution of 150 mL. 
After each removal, the solution was immediately filtered with 0,22 µm Millipore
®
 
filters and analysed with an ICP-OES spectrometer (Optima 8300 ICP-OES, 
PerkinElmer, Inc., Shelton, CT, USA). The calibration curves were obtained from 
standard solutions containing Ca, Na, P, Si, and Nb. In order to ensure the accuracy of 
the calibration curve, the standard sample concentrations were measured periodically. 
Three replicates were measured for each element. The results obtained for the same 
element from different emission lines were averaged. Each point of the graphs shown is 
the result of the average of three dissolution experiments. Elemental concentration was 
reported in ppm. 
Formation Rate of Calcium Phosphate Layer determined by 
31
P MAS NMR 
Spectroscopy. The rate of formation of the calcium phosphate layer on bioglass 
surfaces was monitored by 
31
P MAS NMR. Samples were prepared by adding 50 mg of 
bioactive glass particles to 5 mL of simulated body fluid (SBF)
56
 (see supplementary 
information – Table SI1), and stirring in a thermostatic bath at 37 °C. After 3, 12, 24 
and 48 hours the solution was filtered and the remaining powder was immediately dried 
between two filter papers. Soon after the drying procedure the material was packaged in 
the rotor and analysed by 
31
P MAS NMR. 
31
P MAS NMR study was carried out using an FT-NMR (AVANCE II+ 400, 
9.04T, Bruker, Rheinstetten/Karlsruhe, Germany) at the resonance frequency 161.98 
MHz, using standard Bruker double-resonance magic-angle sample spinning (MAS) 
probes. The glass particles were packed into a 4-mm cylindrical zirconia rotor and spun 
at the MAS frequency at the magic angle to remove any anisotropy effects. The samples 
were spun at 10 kHz at the ambient probe temperature. The 
31
P MAS spectra were 
obtained using a high-power decoupling (HPDEC) pulse sequence with 2.50 μs pulses, 
82 ms acquisitions, 5 s recycle delays, a 100 kHz spectral width, and 1024 scans. The 
31
P chemical shifts were referenced to 85% H3PO4. The spectra were processed with 
TopSpin 2.1.6 software using Fourier transforms and an exponential filter of 50 Hz. The 
phase was manually adjusted, and the baseline was obtained using a five-order 
polynomial function.  
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Culture of Human Embryonic Stem Cells (hESCs). Human Embryonic Stem 
Cells (hES cells) CCTL12 were cultured in complete human embryonic stem cell 
medium (cHES) composed of Dulbecco's Modified Eagle Medium Nutrient Mixture F-
12 (DMEM/F-12) supplemented with 2 mM of L-glutamine (Gibco
®
, Thermo Fisher 
Scientific Inc.) and 10 ng/mL of fibroblast growth factor 2 (FGF2, PepTech 
Corporation, Bedford, MA, USA). Before being used with hES cells, cHES was 
conditioned by incubation for 24 h with confluent cultures of mouse embryonic 
fibroblasts. 
 
For all cell experiments the hES cells were cultured in flasks previously coated 
with BD Matrigel™ and using one of the following four culture media: (a) cHES; (b) 
Osteogenic Medium (OS), composed by cHES supplemented with 3mM β-
glycerolphosphate, 0.1 mM ascorbic acid and 10
-8 
M dexamethasone (Sigma-Aldrich, 
St. Louis, MO, USA); (c) BG45S5 medium, in which BG45S5 powder was mixed with 
cHES medium at 10 mg/mL; and (d) BGPN1.3 medium, in which Nb-substituted 
bioglass was mixed with cHES at a concentration of 10 mg/mL. All glass-conditioned 
media were sterilized using a 0.22 µm pore filter (which also removed the powder 
particles) prior treating the cells. Cells were incubated at 37 ºC in a humid 5% CO2 
atmosphere. 
Cell Viability – Resazurin Assay. Cell viability was determined by means of 
resazurin assay (Sigma-Aldrich, St. Louis, MO, USA). The culture medium was 
supplemented with 5 µM of resazurin and the cells were incubated at 37 °C and 5% CO2 
for 4-6 hours. The total metabolic activity was measured by scanning the cell plate at a 
plate reader (Synergy HT, BioTek
®
 Instruments, Inc, Winooski, VT, USA) on the 
fluorometry mode with excitation filters centred at wavelengths of 540 nm and 590 nm. 
Matrix Mineralization. The Alizarin red stains intracellular calcium deposits 
and calcium bound to proteins and proteoglycans
57
. This dye was used to analyse the 
deposition of mineralized matrix by osteoblasts, which is a marker of cell maturation. 
The test was conducted after 21 days of cell culture (the time required for observing 
matrix mineralization) within the four different experimental media. For the test, the cell 
monolayers were fixed with 70% ethanol for 1 hour at 4 °C and incubated in 1% 
Alizarin Red (Sigma-Aldrich, St. Louis, MO, USA) for 10 minutes. After this period 
five washes in distilled water were carried out and microphotographs at 100× 
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magnification were taken from each well. Each treatment was applied to five wells per 
plate and the whole assay was performed in duplicate. 
In Vivo Assessment. In order to test the biological response incited by the 
bioactive glass, glass rods were implanted into rat tibia. For this, Brazilian College of 
Animal Experimentation (BCAE) guidelines were followed, and experiments were 
approved by Ethics Committee in Animal Use – ECAU/Unicamp (Protocol nº 2777-1). 
Rods composed of different types of glass (BGPN1.3, BGPN2.6, and BG45S5) were 
implanted into a round defect created in the tibia of rats that had been anesthetized with 
a mixture of ketamine (ANASEDAN
®
) at 80 mg/kg and xylazine (DOPALEN
®
) at 
10mg/kg. Five rats were used per group. After pulling aside the periosteum a round 
transcortical defect was created using a spherical threfine bur (JET®) with a diameter of 
2 mm. The glass rod (4 mm length × 2 mm diameter) was carefully introduced into the 
defect until total coupling, then the periosteum and the skin were sutured. After 14 or 28 
days, the animals were euthanized, and the tibia was obtained from the animals and 
fixed for 24 h at 4 ºC in 10% zinc-buffered formalin (Sigma-Aldrich®). After fixation, 
they were decalcified in 5% EDTA (Synth Labsynth, Diadema, SP, Brazil), the glass 
rod was then carefully removed and the bones were paraffin-embedded and sectioned. 
Systemic Toxicity. To assess the systemic toxicity of the glass implants we 
calculated the relative weights of rats‟ liver and kidneys. For this, immediately after 
euthanasia (14 or 28 days after implantation), liver and kidneys were dissected from the 
five rats of each group and weighed with a high precision scale (Unibloc®). The organ 
relative weights were calculated as the ratio between organ weight and body weight. 
Morphometry. All histological sections were stained with haematoxylin and 
eosin dyes. A light microscope (80i) with a camera (DS-Ri1) and software (NIS-
Elements software Advanced Research 3.0), all made by Nikon Corporation, Tokyo, 
Japan, were used to quantify the following parameters: 
Area of newly-formed subperiostal bone. The area of the newly-formed 
subperiostal bone was measured at one field of each side of the cortical defect, directly 
underneath the periosteum and adjacent to where the glass rod was previously located, 
at 400× magnification. Five non-consecutive histological sections were analysed per 
animal. Five rats were used per group (n=5 per group). Thus, the mean and standard 
error of the mean were registered and further compared (Figure SI3). 
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Thickness of newly-formed bone layer. Along the bone layer that formed 
around the implant we performed 20 measurements of thickness. All measurements 
were performed at 400× magnification. Five rats were used per group (n=5 per group). 
The mean and standard error of the mean were registered and further compared (Figure 
SI4).  
Statistical Analysis. We used One-way ANOVA followed by Student Newman-
Keuls test to compare the organ relative weights. Comparisons between means of 
subperiostal newly-formed bone and thickness of the bone layer formed around the 
implant were made using ANOVA one-way test with Tukey (homogeneous variances) 
or Games-Howell (non-homogeneous variances) post-hoc. For comparisons between the 
amounts of trabecular bone formed at 14 post-operative days, a Kruskal-Wallis test was 
used due to the non-normality of the data, matching the control group with each of the 
other groups through Mann-Whitney tests post hoc. For all tests α = 0.05 was assumed. 
All data are presented as means and standard errors. 
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Supplementary Information – SI 
 
SI1. Glass rods preparation 
 
 
Figure SI1. Devices used for the preparation of glass rods for in vivo tests: Graphite 
mould and suction system to force filling of the glass in the graphite mould. The 
vacuum pump was used to suction the molten glass, overcoming the high surface 
tension of the melt and allowing it to fill the 2 mm diameter graphite mould. 
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SI2. Preparation of SBF solution 
The acellular simulated body fluid (SBF) solution was prepared with 
concentrations of ions equal to those of blood plasma, including Cl
-
 and HCO3
-
 .The pH 
value of 7.40 was obtained using the Hepes buffer at concentration 50.69 mmol/L. 
Details about the concentrations of the ions present in the SBF solution is presented in 
Table SI. 
Table SI1. Nominal ion concentrations of the SBF in comparison with those of 
human blood plasma. 
 
 
 
 
 
 
 
Ions 
Concentration/mM 
Blood Plasma SBF 
Na
+
 142.0 142.0 
K
+
 5.0 5.0 
Mg
2+
 1.5 1.5 
Ca
2+
 2.5 2.5 
Cl
-
 103.0 103.0 
HCO3
2-
 27.0 27.0 
HPO4
2-
 1.0 1.0 
SO4
2-
 0.5 0.5 
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SI3. Ion release in 50.69 mM HEPES solution at pH 7.40 for BG45S5 and 
Nb-substituted bioactive glass 
Figure SI3 shows a linear function with the square root of time up to about 120 
min for all compositions.  
 
Figure SI3. ICP data: ion release as a function of square root of time in 50.69 mM 
HEPES solution at pH 7.40 for BG45S5 and Nb-substituted bioactive glass. The data 
displayed in (a), (b), (c), and (d) are related to leached of Na, Ca, Si, and P species, 
respectively, from glass derived from substitution of P2O5 by Nb2O5. Lines are linear 
regression of dissolution data up to 120 min. 
The elemental concentrations of sodium, calcium, silicon, and phosphorus 
exhibited a linear function of the square root of time up to about 120 min for all 
compositions, which indicates a two-step degradation mechanism with initial 
dissolution controlled by diffusion (exhibits a t
1/2 
dependence). 
(b)(a)
(c) (d)
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SI4. Morphometry  
 
Figure SI4.1. Micrographs showing H&E stained histological sections of rat tibia 
tissues at 40×, 100×, 200×, and 400× magnifications and quantification of the area of 
newly-formed subperiostal bone. The area of the newly-formed subperiostal bone was 
measured in one field of each side of the cortical defect, directly underneath the 
periosteum and adjacent to where the glass rod was previously located at 400× 
magnification. Five non-consecutive histological sections were analysed per animal. 
Five rats were used per group (n = 5 per group). Thus, the mean and the standard error 
of the mean were recorded and further compared 
 
(a)
(c) (d)
(b)
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Figure SI4.2. Micrographs showing H&E stained histological sections of rat 
tibia at 40×, 100×, 200×, and 400× magnifications. Measurement of the thickness of 
newly-formed bone layer that formed around the implant was repeated 20 times, and all 
measurements were performed at 400× magnification. Five rats were used per group (n 
= 5 per group). The mean and the standard error of the mean were recorded and further 
compared. 
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Abstract  
This paper reports and discusses the results of a systematic evaluation of the 
bioactive properties of Nb-substituted silicate glass derived from Bioglass
®
 45S5. 
Substituting low concentration of Nb2O5 caused minimal variation in the dissolution 
compared to 45S5 apart from the presence of Nb ions. An amorphous calcium 
phosphate / apatite layer was seen to form on 45S5 BG and the 1% doped Nb glass 
within 3 hours, whilst 2.5 % Nb glass took 12 hours.  Cytocompatibility of Nb-doped 
glass and bone marrow-derived mesenchymal stem cells (BMMSCs) revealed that Nb-
substituted glass is not toxic to BMMSCs. In addition, replacing 1 mol% of SiO2 with 1 
mol% of Nb2O5 significantly enhanced cell proliferation after four days of treatment. 
The compositions BGSN1 and BGSN2.5 stimulated osteogenic differentiation of BM-
derived MSCs after 21 days of treatment. For the in vivo experiments, trial glass rods 
were implanted into circular defects in rat tibia in order to evaluate their 
osteoconductivity and osteostimulation. Two morphometric parameters were analyzed: 
(i) thickness of new-formed bone layer and (ii) area of new-formed subperiostal bone. 
Results showed that Nb-doped glass is osteoconductive and osteostimulative. Therefore, 
these results indicate that Nb-substituted glass is suitable for biomedical applications. 
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1. Introduction 
Musculoskeletal disorders are the most widespread human health issue with 
bone fractures standing among the most debilitating ones.
[1]
 Recent investigations 
showed that men and women aged 50-64 account for nearly 30% of most types of 
fractures. Furthermore, most tibia fractures occur in working-age individuals. Therefore, 
fractures not only compromise the quality of life of people but also represent an 
economic burden due to the medical costs associated with fracture repair, the related 
lost work productivity and disability to the working age population.
[1, 2]
  
The progressive increase in the number of fractures has prompted the 
development of synthetic materials for bone replacement. Currently, the most 
widespread treatments for bone replacement include autologous bone, allografts, 
xenografts, and various types of biomaterials.
[3]
 Autologous bone is considered a gold 
standard for the treatment of large fractures but presents some drawbacks, such as donor 
site morbidity, limited availability, and some degree of resorption. Both allografts and 
xenografts possess potential risk of disease transmission, unpredictable resorption rate, 
and graft rejection. To overcome these challenges, synthetic materials have been 
developed, and bioactive glass-ceramics are therefore of great importance.
[3-6]
  
The history of biomaterials designed to treat bone disorders can be easily 
distinguished in three different generations. The first generation of biomaterials was 
designed with the only requirement of achieving similar physical properties of those 
from the replaced tissue whilst being biocompatible (e.g. metallic implants).
[7-10]
 The 
second generation of biomaterials was defined by their ability to interact with biological 
environment to enhance tissue bonding as well as progressively degrade while the new 
tissue regenerates and heals (e.g. hydroxyapatite).
[8]
 Today, we are in the era of third 
generation of biomaterials, which have the additional ability to stimulate specific 
cellular responses at the molecular level (e.g. Bioglass
®
 45S5).
[8-10]
  
The first biomaterial of the third generation was the Bioglass
®
 45S5.
[7]
 This 
biomaterial is a glass that is biocompatible and also forms bonds with hard and soft 
tissues, which ultimately optimizes the stability and lifespan of implants. Many 
investigations describe several biological properties of Bioglass
® 
45S5, such as 
angiogenesis, osteostimulation, osteoconduction, and osteoinduction, which are 
essential for a biomaterial for bone replacement.
[8]
 These effects on living tissues are 
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determined by the chemical composition of the glass. Hence, several researchers have 
been designing variations of the original Bioglass
®
 45S5 in order to improve its 
mechanical and biological performance.
[4, 6, 8, 9, 11-14]
 
Recent investigations reported the ability of niobium to optimize mechanical and 
biological performance of synthetic implants.
[1, 3, 9, 11, 12, 14, 15]
 Niobium first appeared in 
biomaterials as a component of metallic alloys.
[16]
 The introduction of Nb in alloys 
substituting vanadium, for instance, was shown to enhance biocompatibility.
[17]
 In one 
study Nb-2Zr was reported to exhibit excellent corrosion resistance, fatigue strength, 
and crack propagation in simulated body fluids.
[17, 18]
 It is noteworthy that Nb2O5 is an 
effective nucleating agent and generally leads to the development of glass-ceramic in 
silica-poor compositions, such as Bioglass
®
 45S5.
[7]
  
In one of our previous studies, we replaced the network former P2O5 with Nb2O5 
and undertook a detailed structural characterization using 
29
Si, 
31
P, and 
23
Na solid-state 
MAS NMR and Raman spectroscopy, we concluded that Nb2O5 participates in the 
silicate network by breaking the Si-O-Si bonds to form structures, such as -Si-O-Nb-O-
Si- chains.
[14, 19, 20]
 These alterations modified the glass dissolution rate and magnitude, 
which we believe increases the lixiviation of ions with biological importance such as Si, 
Ca, Na, and Nb.
[20]
 Some recent investigations incorporated niobium into the structure 
of fluorapatites and phosphate-inverted glass and tested their cytocompatibility, 
osteostimulation and osteoinduction.
[11, 12]
 They observed that the presence of niobium 
resulted in greater biocompatibility and enhanced bioactive properties.
[3, 11, 12]
 
Furthermore, osteogenic differentiation of human Mesenchymal Stem Cells (hMSCs) 
was achieved after 21 days of culture on Nb-doped fluorapatite glass-ceramics.
[3]
 Nb 
doped glasses are also reported into increase vascularization 
[21]
. Even though Nb-
substituted silicate glass appears to possess interesting bioactive properties, its effect 
over pluripotent cells and bone regeneration has not been investigated so far.  
The present study aimed to evaluate the cytocompatibility, osteostimulation, and 
osteoinduction of Nb-containing bioactive glass. For this purpose in vitro and in vivo 
experiments were carried out. In the in vivo assay, glass rods were implanted into 
circular defects in rat tibia and bone formation was quantified. The in vitro experiments 
consisted of treating bone-marrow-derived mesenchymal stem cells (BMMSCs) isolated 
from rats with the dissolution products from the glass and verifying their viability and 
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osteogenic differentiation. We also investigated the leaching profile of Si, Ca, Na, P, 
and Nb species from the bioglass using ICP as well as the kinetics of apatite formation 
using P NMR. 
2. Results and Discussion 
2.1 Glass preparation 
A series of Nb doped bioactive glasses were successfully prepared using the 
melt quench technique. The glass compositions were based on Bioglass® 45S5 with 1, 
2.5 and 5 mol %  of the SiO2 concentration replaced by Nb2O5 as shown in Table 1. 
(Bioglass
®
 45S5 was used as the control and all glasses had a fixed Na2O:CaO:P2O5 
ratios. Despite Nb being a known nucleating element the glasses there were no visible 
signs of crystallization.
[14]
  
2.2 Dissolution studies.  
Figure 1 illustrates the release of Na, Ca, Si and P from the glass and Figure 2 
shows the concentration of Nb ions as determined by inductively coupled plasma 
optical emission spectrometry (ICP-OES). The release of soluble ions from bioactive 
glasses is known to be the key first step in the bio-mineralization process as described 
by Clark and Hench.
[7, 10, 22]
 The release of Ca and P creates a supersaturated solution 
which then precipitates into amorphous calcium phosphate which then crystallizes in 
apatite. Furthermore, the controlled release of Si, Ca, Na, P, and Nb species from the 
bioglass has been associated with the promotion of bioactivity, angiogenesis, 
osteostimulation, osteoconduction, and other important properties for bone 
regeneration.
[2, 8-10]
 The 45S5 bioglass composition is also presented for the purpose of 
comparison 
As shown there is a rapid release of ions following immersion in HERPES 
solution. From the release of Na and Ca ions (Figure 1 a, b) it appears at first glance as 
though the 45S5 bioglass is the most soluble and that the solubility decreases upon 
increasing concentrations of Nb. However it is important to note that the molar mass of 
Nb2O5 is ~ 4.4 times heavier than SiO2. Therefore a 300 mg sample of BGSN5 will 
contain 15% less CaO, Na2O and P2O5 compared to BG45S5. Taking this into 
consideration and given the errors the release of Ca and Na is similar for the glasses 
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with the exception of the BGSN5 which is clearly much less soluble. The Si 
concentrations shows a slight increase in solubility for the 1 and 2.5% Nb glasses 
despite it having a lower SiO2 concentration.    
The increase in Si solubility is attributed to the degree of matrix fragmentation 
caused by both the reduction of Si and more importantly the additional oxygen atoms 
provided by Nb2O5 compared to SiO2. The higher the niobium content the more non-
bridging oxygen atoms and the greater the number of Si-O-Nb bonds.
[14, 19, 20]
  
The release profile of phosphorus suggests a maximum concentration 
(approximately the solubility limit), from which there is a dramatic reduction, 
presumably associated with the removal of some of the soluble phosphate species to 
form the calcium phosphate layer on the bioglass surface (Figure 1d). The results 
indicate that an amorphous calcium phosphate is rapidly deposited for BG45S5 and 
BGSN1, with delay and a reduction for BGSN2.5 whilst BGSN5 appears to insoluble to 
release sufficient P (or Ca) to begin to form ACP. 
A characteristic common to all leaching curves for sodium, calcium, silicon, and 
phosphorus species in the earliest dipping times is the mechanism of the species 
lixiviation. The initial elemental concentrations up to about 120 min for all 
compositions are a linear function of the square root of time, which indicates a 
diffusion-controlled process (Supplementary Information - Figure SI1 a-d). 
The profile shape of niobium species at early soaking times are similar to those 
observed for P, i.e., a sudden increase in the Nb concentration in the medium, reaching a 
maximum value, followed by a characteristic reduction of concentration value for each 
glass. This initial increasing is related to the leaching of niobium species near surface 
and/or release of isolated NbO6 units, which are more labile since their release does not 
require extra energy to break bonds in comparison with the Nb-O-Nb groups.. The rate 
at which the niobium species are removed from the solution is gradual and can be 
mostly attributed to polymerization of the niobate species (Nb-O-Nb), which are 
continuously subtracted from the medium to form the niobium gel layer on the bioglass 
surface.
[20]
 The Nb-OH groups are chemically stable (Brønsted and Lewis acid sites), as 
well as effective nucleation centers for the removal of the leached niobium species from 
the glass.
[14]
 Consequently, the concentration of free niobium decreases as the niobium 
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gel layer is established on the surface of the bioglass, i.e., the limit solubility of niobium 
is reduced. 
2.3 Apatite layer formation ability by 
31
P MAS NMR spectroscopy 
Amorphous calcium phoasphate / apatite formation on the bioglass surface in 
simulated body fluid (SBF) has been verified by 
31
P MAS NMR (Figure 3 (a-d)). As 
shown the local structural arrangement of phosphorus changes rapidly even for early 
soaking times.
[6, 20]
 
The 
31
P MAS NMR spectra of unreacted BG45S5, BGSN1, BGSN2.5 and 
BGSN5 exhibit a single broad resonance around 11 ppm with peak maximum at 11.9, 
11.8, 11.6 and 8.5 ppm, respectively. The 
31
P resonances are attributed to the PQ
0
 
isolated orthophosphate units (charge balanced byNa
+
 and Ca
2+
.
[20, 23]
 In addition, as the 
niobium content increases there is a tiny shift to lower frequencies followed by a more 
significant shift for the BGSN5 suggesting that Nb interacts with phosphorus, 
presumably forming P-O-Nb bonds. The data extracted from the 
31
P MAS NMR spectra 
such as peak positions and full width half maximums (FWHM) for BG45S5 and Nb-
substituted glass, unreacted and after 3, 12, and 24 hours of immersion in in simulated 
body fluid (SBF) are listed Table 2.  
31
P MAS NMR data show a trend that describes the evolution in the chemical 
environment of the phosphorus during the chemical transformations at the 
bioglass/solution interface as a function of the soaking time in SBF. All 
31
P resonances 
are characterized by notable shift to lower frequencies during the soaking time in SBF, 
reaching the frequency of approximately 4 ppm, which is similar to the signal observed 
in the spectrum of hydroxyapatite. Such spectral changes and the decrease in FWHM 
values describe the partial degradation of glass and precipitation of amorphous calcium 
phosphate and its progressive crystallization.
[20]
 
31
P MAS NMR spectra for BG45S5 
(Figure 3a) and BGSN1 (Figure 3b) suggest that 3 hours of incubation in SBF are 
enough to establish an ACP/ apatite layer. While for BGSN2.5 glass the time required is 
considerably longer, approximately 12 hours (Figure 3c). Although subtle, the changes 
observed in the BGSN2.5 spectrum in the range of 13-24 hours are related mainly to the 
gradual increase in the crystallinity of calcium phosphate (increase of long-range order). 
In contrast, 
31
P MAS NMR spectrum for the BGSN5 exhibit a progressive increase in 
the FWHM values of the resonance peak as a function of the soaking time in SBF 
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(Figure 3d). This is a result of some P remaining in the glass network at ~11ppm whilst 
some P starts to form an ACP/ apatite precipitated on the glass surface ~4ppm resulting 
in a much wider distribution of frequencies. For the BG45S5, BGSN1 and BGSN2.5 
samples, almost all of the phosphorus present in the glass network is continuously 
leached into the solution, where it is precipitated in the form of calcium phosphate in 
the gel layer (silica- and/or niobosilica-gel) formed on the bioglass surface.  
In summary, all vitreous compositions have been able to form the phosphate 
layer, but as the niobium content increases the chemical stability of the bioglass 
increases, and the dependence of an external source of phosphorus for apatite 
composition increases. In accordance with this assumption, 
31
P MAS NMR spectra 
display resonance peaks with slight asymmetry on the left-hand side of the peak owing 
to the residual glass fraction. 
2.4 Cytocompatibility assessment. The cytocompatibility is an essential feature 
that must be ensured in any type of biomaterial. Any sign of toxicity may represent a 
risk for the recipient organism and therefore must be avoided. In this work we evaluated 
the cytocompatibility of the dissolution products of different compositions of Nb-doped 
glass (BGSN1, BGSN2.5 and BGSN5) with Bioglass
® 
45S5 as the control with rat bone 
marrow mesenchymal stem cells (BM-MSCs) by MTT and Live/Dead assay. We 
treated cells with culture media conditioned with the dissolution products of the 
different glasses for up to four days. Cells treated with complete DMEM were used as 
positive controls meanwhile cells killed with dimethyl sulfoxide (DMSO) or 70% 
Methanol served as negative controls. None of the glass-conditioned media was 
cytotoxic to this cell type (Figures 4a and 4b). This result demonstrates that the 
incorporation of niobium dioxide into the structure of Bioglass
®
 45S5 does not 
compromise its cytocompatibility. As it can be seen on figure 4b the viability of cells 
treated with medium conditioned with the composition BGSN1 were considerably 
higher than the Bioglass
®
 45S5 glass and the positive control group (complete DMEM) 
which indicates that this glass enhances cell proliferation. 
Several other studies have also shown that the addition of niobium into 
biomaterials do not result in cytotoxicity. These investigations include tests with 
different materials such as fluorapatite glass-ceramics,
[3]
 phosphate glasses,
[24]
 bioglass-
niobium granules,
[15]
 hydroxyapatite bioceramics,
[25]
 and calcium silicate cements with 
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different cell lines.
[26]
 In one of these assays human osteogenic cells (SAOS) were 
incubated with Nb-doped hydroxyapatite for 72 hours and cell viability was tested by 
means of a MTT assay. They observed no difference or even a statistically significant 
increase in cell proliferation when compared to the control group (reference material) 
which allowed them to conclude that Nb-doped hydroxyapatite has the ability to support 
cell proliferation.
[25]
 Furthermore, a very recent investigation evaluated the 
cytocompatibility of calcium silicate-based cements combined with niobium oxide 
(Nb2O5) micro and nanoparticles, comparing the response in four different cell lines: (a) 
human dental pulp cells – hDPCs; (b) human dental follicle cells – hDFCs; (c) human 
osteoblast-like cells (SAOS-2); and (d) mouse periodontal ligament cells – mPDL. After 
24 hours of incubation within media conditioned with the materials they measured 
cellular viability by means of MTT assay. The authors concluded that calcium silicate 
cements combined with Nb2O5 micro and nanoparticles presented cytocompatibility and 
can be used as an alternative radiopacifier agent for calcium silicate cements. Therefore, 
our results complement the existing literature demonstrating that Nb-doped bioactive 
glass is cytocompatible and also constitutes a safe biomaterial for biomedical 
applications.  
2.5 Osteoinductive potential of Nb-containing bioglass. Over the past few 
years the role of engineered scaffolds complexed with mesenchymal stem cells (MSCs) 
for bone regeneration has been a main research topic in regenerative medicine.
[27-29]
 The 
bone- marrow- derived mesenchymal stem cells (BM-MSCs) are multipotent cells that 
are able to self-renewal and to differentiate into several cell types depending on which 
chemical or mechanical stimulus they are subjected.
[30]
 The bone formation that is 
required for integration of biomaterials relies on the presence of multipotent cells that 
are capable of differentiating into osteoblasts.
[30]
 As BM-MSCs constitute one of the 
most abundant multipotent cell types present at the fracture site they play major roles in 
supporting faster bone formation along implants.   
In some studies MSCs were complexed with different types of biomaterials such 
as calcium phosphate
[24, 28]
 and biodegradable poly(lactide) (PLA) scaffolds.
[27]
 The 
incorporation of human BM-MSCs in macroporous calcium phosphate cement (CPC) 
promoted great cell attachment, osteogenic differentiation and mineralization. When 
these BM-MSCs – containing scaffolds were used to treat cavarials defects in rats new 
bone and blood vessels were generated between 4 and 24 postoperative weeks. In 
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summary, the authors concluded that seeding stem cells with CPC increased new bone 
and new blood vessel density, compared to CPC without cells, suggesting this material 
can be used for craniofacial and orthopedic applications.
[28]
 In other very recent 
investigation
[27]
 human gingival mesenchymal stem cells (hGMSCs) were cultured with 
three-dimensional printed PLA scaffolds pre-treated with hGMSCs – derived - extra 
cellular vesicles (EVs) in order to test the in vitro osteogenic performance of this 
material by means of alizarin red staining, gene expression of RUNX2 and BMP-2 (RT-
PCR), and the concentration of the proteins RUNX2, BMP-2, and β-Actin (Western 
Blot). The combination of hGMSCs + 3D-PLA + EVs promoted excellent osteogenic 
differentiation indicating that the combination of pluripotent cells and inorganic 
scaffolds enhances bone regeneration of calvarial defects.
[27]
   
The formation of bone requires not only the recruitment and/or migration of 
potentially osteogenic cells but also their differentiation towards the osteoblastic 
lineage. We believe that scaffolds composed of Nb-doped glass may favor MSCs to 
differentiate into osteoblasts because some investigations have reported that the 
incorporation of niobium into other types of biomaterials such as fluorapatites and 
phosphate-inverted glass has incited osteogenic differentiation of hMSCs
2
 and 
maturation of mouse osteoblast-like cells (MC3T3- E1 cell).
[11]
 The study of Obata and 
his collaborators
[11]
 is of particular importance for the scope of the present work because 
they tested the osteostimulative capacity of niobium ions over MC3T3-E1 cells. They 
reported that both ALP activity and calcium deposition of MC3T3-E1 cells was 
significantly higher in the medium containing niobium at a concentration of 10
−7 
M
 
when compared with control or other Nb- containing media, even though none of the 
tested media contained osteogenic supplements. The authors proposed that this may 
indicate that the niobium ions not only enhance but also induce osteogenic 
differentiation.
[11]
  
The osteoinduction capacity of Nb- doped bioactive glass may result in a higher 
number of osteoblasts within the implant and consequently at the fracture site. In order 
to test the capacity of different compositions of Nb-doped bioactive glass to stimulate 
the osteogenic differentiation of BM-MSCs we stained mineralized nodules at the 
extracellular matrix with Alizarin Red after 21 days of treatment with culture media 
conditioned with the dissolution products of different Nb-containing glasses. We also 
marked matrix-mineralization-related protein osteocalcin with and fluorescent antibody 
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and obtained micrographs using a Laser Scanning Confocal Microscope to demonstrate 
the presence of this protein which is also a marker of osteogenic differentiation. 
The formation of mineralized nodules marks the final step of the process of 
osteogenic differentiation. In short, this process follows the subsequent stages: (i) 
proliferation of multipotent cells (as differentiation only progresses after this step we 
chose to wait BM-MSCs to form a monolayer before starting to treat them with the 
different cell media); (ii) formation of non-mineralized matrix mostly composed of type 
I collagen; and (iii) mineralization of the matrix forming calcium-rich nodules. Our 
results showed that the compositions BGSN1 and BGSN2.5 stimulated the formation of 
nodules comparable to the positive control group (MSCs treated with an osteogenic 
culture medium) (Figure 5, six upper squares) which is an ultimate sign of osteogenic 
differentiation. In addition, osteocalcin was present in the bone matrix corroborating 
with the previous result (Figure 5, four lower squares). These results support the claim 
that Nb-doped bioactive glass may be used to produce high-bioactive scaffolds for bone 
tissue engineering because it not only serves to support migration of BM-MSCs but also 
stimulates osteogenic differentiation of these cells, increasing the population of mature 
secretory osteoblasts in the fracture site which may hasten bone regeneration.  
2.6 Bone formation stimulated by Nb-containing bioactive glasses. In vivo 
experiments were performed in order to analyze the properties of osteoconductivity and 
osteostimulation of Nb-containing glass. Osteoconductivity is often referred in the 
biomaterial literature as the capacity of a material to allow bone to grow onto its 
surface.
[31]
 Despite this definition correctly describes the event it does not explain 
exactly how it happens. In fact, what makes a new bone form onto a material‟s surface 
in a particular direction is the migration of multipotent cells coming from the bone-
marrow (bone marrow-derived MSCs), blood (blood- derived MSCs) or, in a minor 
extent, from surrounding tissues (e.g. myocytes from the muscles and pericytes from the 
blood vessels). Just the migratory activity of these cells over the surface responds for 
the expansion of a bone spicule.
[32]
 As soon as a material is placed into a surgically 
made defect (as in our experiment) it rapidly undertakes a series of ion exchange with 
the body fluid that culminates with a drastic increase in the surface‟s roughness (Figure 
6).  
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Rough surfaces are more easily coated with many proteins, lipids, ions, and 
sugars which will dictate which cell types will subsequently attach.
[32]
 It is known that 
some characteristics of the material‟s surface, such as its topography, chemical 
composition, charge, and energy, directly influence protein adsorption and consequently 
cell adhesion and migration.
[32]
 Hence, biomaterials designed for bone replacement must 
provide suitable surface for the adhesion and migration of osteogenic cells that will 
populate the surface, differentiate into osteoblasts and produce a mineralized matrix. As 
the composition BGSN1 showed better performance in the in vitro experiments and a 
significant increase in topographical complexity of its surface it was chosen for the in 
vivo investigation. We implanted glass rods made of BGSN1 into the tibia of rats and 
looked for the formation of a bone layer around the implant. The composition BG45S5 
was used as a control. We observed the presence of a bone layer around both glass 
compositions and calculated their thickness in order to compare the groups (Figure 7). 
In the present work we demonstrate in vivo osteoconductivity of Nb2O5-
containing bioactive glass. Nevertheless, the ability of other type of niobium- containing 
materials to support bone growth onto their surfaces was demonstrated in vivo by 
Matsuno and his collaborators.
[33]
 They introduced a wire of 99.9% niobium, 1.0 Ø x 
7.0mm in size in rat femur bone marrow and evaluated bone formation around the 
implant after 14 and 28 days. They observed new bone formation onto niobium 
implant‟s surface after 28 days, confirming its osteocondutivity.[33] In another 
investigation cylindrical implant made of Ti-Nb alloy was implanted into medial tibia of 
beagles for 2, 4 and 12 weeks.
[34]
 New bone formation was observed to grow in contact 
with the material‟s surface after 4 weeks. In the same study the authors reported that the 
incorporation of Nb to the metallic alloy increased its surface roughness (Ti-Nb: 1.79 ± 
0.23 µm compared to pure Ti: 1.63 ± 0.17 µm) and reduced its contact angle (Ti-Nb: 
81.75 ± 2.94º compared to pure Ti: 96.46 ± 3.56º) (more hydrophilic). It is generally 
accepted that osteogenic cells respond to microroughness (<25µm) and tend to adhere to 
more hydrophilic surfaces.
[35]
 
As a matter of fact the surface characteristics determine which types of proteins 
will adsorb and as a consequence which cell types will be attracted to it.
[32]
 Thus, it is 
believed that the incorporation of Nb into these materials provided them with a more 
suitable surface for adhesion and maturation of osteogenic cells. We believe that a 
similar mechanism was involved in the formation of the bone layer onto BG45S5 and 
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BGNS1 (Figure 7). We suggest that osteogenic cells coming from the bone marrow and 
the periosteum contributed to the observed bone formation. As the surface of the 
material was in direct contact with the periosteum at the outer surface of tibia cortical 
we believe that osteogenic cells started to migrate from the periosteum onto material‟s 
surface by haptotaxic migratory movement. This pattern of migration is described as a 
directional motility of cells towards cellular adhesion sites or surface-bound 
chemoattractans.
[36]
 In addition, bone- marrow- derived MSCs also may have 
substantially contributed to bone formation attaching to the material‟s surface probably 
attracted by its favorable physical, chemical, and/or biological characteristics. The bone 
formation on the surface reveals that it presented ideal features that favored protein 
adsorption and consequently cell migration and adhesion followed by subsequent 
osteogenic differentiation. To confirm this scenario and fully understand the 
mechanisms underlying the formation of the observed bone layer more comprehensive 
studies should focus on the characteristics of Nb- containing bioactive glass such as 
surface topography and hydrophobicity.  
It is worth mentioning that direct contact is not the only way by which materials 
can influence living cells. In fact, inorganic ions were shown to influence formation, 
regulation and maintenance of bone.
[37]
 In our dissolution studies we showed that 
BGSN1 presents a pattern of ion release very similar to BG45S5 except for the Nb, 
obviously only found in the Nb- containing glass. The biological roles of BG45S5- 
derived ions are well described in the literature,
[37, 38]
 whereas the role of Nb soluble 
ions over osteogenic cells started to be investigated only recently.
[11]
 Ca ions were 
shown to affect osteoblasts in vitro. In low concentrations (2-4 mmol) Ca stimulates 
osteoblasts to proliferate whereas in medium concentrations it boosted cell 
differentiation and matrix mineralization. In high concentration (> 10 mmol) Ca ions 
were shown to be toxic to cells.
[39]
 Soluble P was reported to promote expression of 
matrix 1a protein (MGP) which is an essential protein for bone formation.
[39]
 It is well 
accepted that Si participates in the process of bone formation probably by inducing 
precipitation of hydroxyapatite in the early stages of matrix mineralization.
[36, 37]
 The 
only study that investigated the effect of Nb ions on osteoblast- like cells (MC3T3-E1 
cells) concluded that in a dose- dependent manner (3 x 10
-7
 M) these ions induce 
differentiation and mineralization of osteogenic cells rather than adhesion and 
proliferation.
[11]
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While the investigations of the effect of soluble ions over cells provide good 
insights regarding the probable mechanism by which bioactive materials perform its 
non- contact biological effects it is not without problems. It is important to take into 
account the fact that these ions will mostly be complexed in large molecules, thus, the 
observed effects of the glass- derived ions might actually be caused by the compounds 
of the elemental constituents of the glass rather than individual ions. Despite the 
specific ionic compounds formed after dissolving from the bioactive glasses not being 
well described they were shown to possess an overall effect over gene expression of 
osteoblasts.
[40]
 Xinus et al.
[40]
 prepared a bioactive glass conditioned medium containing 
1% w/v of Bioglass
®
 45S5 in DMEM and filtered the medium to remove glass 
particulates (0.2 µm filter). Thus, they treated human osteoblasts with this medium for 
24 hours and performed cDNA microarrays to analyze gene expression. Their results 
showed that bioglass dissolution products were able to up- regulate many genes related 
to osteoblast metabolism, cell proliferation, cell-cell and matrix-cell adhesion up to 5 
fold.
[40]
 
We believe that immediately after implantation glass rod started to exchange 
ions with the body fluid, releasing ionic products that acted over osteogenic cells 
located in the adjacent periosteum and bone marrow. The glass dissolution products 
may have stimulated periosteal osteogenic cells to differentiate into polarized secretory 
osteoblasts that began to produce new bone onto the preexistent bone promoting 
appositional bone growing forming a very clear cement line (arrows in figure 8).  
This chain of events is believed to have happened for both glass compositions, 
as the two of them showed histological signs of subperiosteal bone formation. The 
comparison of subperiosteal bone area in the BGSN1 group and in the control group 
(BG45S5) showed significant larger bone area in the control group after 28 days of 
implantation [F (3, 16) = 1.881, p= 0.174)] (Figure 8) despite both glasses clearly 
stimulated periosteal cells to differentiate and produce new bone.  
The present study have gathered sufficient information to claim that Nb- 
containing glasses are cytocompatible with BM- derived MSCs in addition to stimulate 
these cells to differentiate into osteoblast. Furthermore, we showed this material possess 
the bioactive properties of osteoconductivity and osteostimulation in vivo.  
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3. Conclusion 
To summarize, our results showed that when incubated in buffered solution the 
glass composition BGSN1 released similar amounts of Ca, Na, P, and Si compared to 
BG45S5. However, BGSN1 also released Nb into the solution. The Nb-containing 
glasses BGSN1 and BGSN2.5 exhibited the ability to form an apatite layer onto their 
surfaces, which is a sign of bioactivity. In addition, the immersion of BGSN1 and 
BG45S5 into complete culture media for 24 h promotes significant increase in surface‟s 
roughness. Furthermore, Nb-doped glasses are non toxic to BM-derived MSCs, instead, 
BGSN1 stimulated greater cell proliferation after up to 4 days of treatment than the 
control group. The dissolution products of the glass compositions BGSN1 and 
BGNS2.5 are osteogenic as they differentiated BM-derived cells towards osteoblast 
lineage after 21 days of treatment. In vivo experiments showed that BGSN1 was 
osteoconductive enabling the formation of a bone layer onto its surface. In addition, 
BGSN1 stimulated the osteogenic cells of the periosteum to form bone (from a very 
clear cement line) which indicates good osteostimulative capacity for this glass 
composition even though it was lower than that stimulated by BG45S5. These results let 
us conclude that the addition of 1% of Nb2O5 substituting SiO2 in Bioglass
®
 45S5 
generates a cytocompatible material with great bioactive properties with significant 
potential for biomedical applications.   
 
 
4. Experimental Section  
Preparation of bioglass samples. The detailed process of preparation of bioglass 
samples is fully described in our previous publications.
[14]
 High purity SiO2, Na2CO3, 
CaCO3, P2O5 powders (>99.9%) (Sigma-aldrich
®
) were weighed to obtain the glass 
compositions depicted in Table 1. The niobium oxide was donated by the CBMM 
(Companhia Brasileira de Metaluria e Mineração, Araxá, Minas Gerais, Brazil). The 
different types of glass were ground and sieved to isolate the desired particle size 
(between 38µm and 53µm). For the in vivo studies cylindrical rods with 4 mm length x 
2 mm diameter were prepared by casting method in a graphite mould. (Supplementary 
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Information - Figure SI1). These rods were annealed at 50 °C below the glass 
transition temperature (Tg) for 12 h and slowly cooled to room temperature to release 
the thermal stress associated with the quenching process.  
Ionic leaching patterns of bioactive glass by ICP-OES. We used inductively 
coupled plasma optical emission spectrometry (ICP-OES) to verify the ionic leaching 
patterns of bioactive glass. In brief: 300 mg of bioglass particles were dispersed in a 
beaker with 200 mL of buffer solution and maintained under continuous stirring 
(stirring rate of 75 rpm), at room temperature. Using a 50.69 mM HEPES (2-(4-(2-
hydroxyethyl)piperazin-1-yl)ethanesulfonic acid) (Sigma-Aldrich®) and 1 mM NaOH 
(Sigma-Aldrich®) the solution pH was adjusted to 7.40. The solution was filtered using 
a 0.22 µm pore filter (Millipore
®
) in order to remove contaminants and aggregates. The 
glass was then added to the solution and allowed to mix for 3, 6, 12, 24 and 48 hours. At 
each time point 10 mL of solution was collected with a syringe and passed through a 
0.22 µm pore filter (Millipore
®
) and analyzed with an ICP-OES spectrometer (Optima 
8300 ICP-OES, PerkinElmer, Inc., Shelton, CT, USA). Three replicates were measured 
for each element. 
Analysis of the calcium phosphate layer by 
31
P MAS NMR spectroscopy. 
31
P 
MAS NMR was performed to analyze the rate of formation of the calcium phosphate 
layer on bioglass surfaces. Samples of 50 mg of bioactive glass particles were added to 
5 mL of simulated body fluid (SBF) (see supplementary information - Figure SI2) 
and the mixture was stirred in a thermostatic bath at 37 °C. After 3, 12, 24 and 48 hours 
the solution was filtered and the remaining powder was immediately dried between two 
filter papers. Soon after the drying procedure the material was packaged into a 4-mm 
cylindrical zirconia rotor and spun at the MAS frequency at the magic angle to remove 
any anisotropy effect. The samples were spun at 10 kHz. The 
31
P MAS spectra were 
obtained using a high-power decoupling (HPDEC) pulse sequence with 2.50 μs pulses, 
82 ms acquisitions, 5 s recycle delays, a 100 kHz spectral width, and 1024 scans. The 
31
P chemical shifts were referenced to 85% H3PO4. The spectra were processed with 
TopSpin 2.1.6 software using Fourier transforms and an exponential filter of 50 Hz. The 
phase was manually adjusted, and the baseline was obtained using a five-order 
polynomial function. 
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Culture of BM- derived Mesenchymal Stem Cells (MSCs). Bone- marrow- 
derived Mesenchymal Stem Cells (BMMSCs) were isolated from the tibia and femoral 
of five adult Wistar rats weighing 250 - 300g.  For this, the bone epiphyses were 
removed and discarded. The bone shafts were centrifuged at 1500 rpm for 15 minutes in 
order to precipitate their bone marrows. The pellet (composed by the precipitated bone 
marrow) was resuspended in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 1% penicillin/streptomycin solution and 10% fetal bovine serum 
(FBS) (Complete DMEM) in a 37 °C–5% CO2 incubator Cells, up to their fourth 
passage, were maintained in  supplemented DMEM . All media were changed every 
other day.  
Cell viability – MTT assay. Cytotoxicity was analyzed using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma-Aldrich, 
St. Louis, MO, USA). For this, 5000 BMMSCs were cultured in conditioned media 
containing 10 mg/mL of each of the glass compositions (BG45S5, BGSN1, BGSN2.5 
and BGSN5), for a period of four days. Cells grown in complete DMEM served as a 
positive control while cells previously incubated in Dimethyl sulfoxide (DMSO) for 30 
minutes served as a negative control. The MTT assay was performed following the 
manufacturer‟s instructions. In short, 12 mM stock solution of MTT was prepared and 
diluted 10 x in phenol red free medium before being added to the cells, which were 
incubated for 4 h at 37 °C. After the incubation 75 μL of medium was replaced by 50 
μL of Dimethyl sulfoxide (DMSO) and left to incubate at 37 °C for 10 min. MTT was 
reduced to formazan by metabolically active cells and the optical density was measured 
using a spectrophotometer (at 570 nm). This assay was performed in quintuplicate. 
Cell viability – Live/Dead assay. 10,000 BM- derived MSCs were seeded per 
well and treated for 72 h with conditioned media containing the dissolution products of 
Bioglass®45S5, BGSN1, BGSN2.5, and BGSN5 at a concentration of 10 mg/mL. 
Following the incubation period, a negative control of dead cells was established by 
incubating cells with 70% methanol for 30 min. Cells treated with regular growth media 
served as a positive control. The polyanionic dye calcein-green is retained within live 
cells, producing an intense uniform green fluorescence. Ethidium homodimer-1 (EthD-
1) enters cells with damaged membranes and undergoes a 40-fold enhancement of 
fluorescence upon binding to nucleic acids, thereby producing a bright red fluorescence 
in dead cells. To stain BM- derived MSCs working concentrations of calcein-green at 2 
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μM and EthD-1 at 4 μM were combined into one solution and used to treat cells. Cells 
were overlaid with 200 μL of staining solution. 
Staining mineralized nodules with Alizarin Red 1%. BM-derived MSCs were 
cultured in complete medium until reach monolayer (~10 days). Following the 
formation of the monolayer cells were treated for three weeks with one of the 
experimental media: (a) complete DMEM; (b) osteogenic medium, composed by 
complete DMEM supplemented with 0.1 mM ascorbic acid, 3mM β-Glycerolphosphate 
and 10
-8
 M dexamethasone (Sigma-Aldrich, St. Louis, MO, USA); (c) BGSN1 
(Complete DMEM + 10mg/mL of BGSN1); (d) BGNS2.5 (Complete DMEM + 
10mg/mL of BGSN2.5; or (e) BGSN5 (Complete DMEM + 10mg/mL BGSN5). After 
21 days of incubation the monolayerswere stained with Alizarin Red 1% (Sigma-
Aldrich, St. Louis, MO, USA) in order to analyze the presence of mineralized nodules, 
which is a marker of osteogenic differentiation. In short, cell monolayers were fixed 
with 70% ethanol for 1 hour at 4 °C and incubated in 1% Alizarin Red for 10 minutes. 
Thus, plates were washed five times with distilled water and microphotographs at 100× 
magnification were taken from each well. Five well were used per group.  
Immunofluorescence for Osteocalcin. 20,000 BM- derived MSCs were cultured 
per well. Cells were treated for 21 days with culture media conditioned with the 
dissolution products of BG45S5 and BGSN1. Cells treated with osteogenic medium 
(StemPro™ Osteogenesis Differentiation Kit, ThermoFisher) were used as a positive 
control. After 21 days of treatment cells were fixed with 4% paraformaldehyde for 30 
minutes and treated with a 0.25% solution of Triton X-100 for 30 minutes. Cells were 
then incubated in Osteocalcin primary antibody (Abcam) at 1:100 for 1 hour at room 
temperature. After washing with saline solution, cells were incubated in the secondary 
antibody (Alexa-Fluor 647 goat to rat, Abcam) for 1 hour at room temperature. The 
cellular nucleuses were stained with DAPI. Images were obtained with a Laser 
Scanning Confocal Microscope (LSCM, Leica TCS SP5) in PMT mode. Reflection 
images of laser in TRANS mode were obtained in order to identify mineralized matrix.  
Atomic force microscopy (AFM). Surface roughness of bioglass before and after 
immersion in culture medium was measured by atomic force microscopy (AFM) using a 
NX-10 atomic force microscope (Park System) operating on intermittent contact. The 
nominal spring constant and resonant frequency of the silicon tip (Nanosensors) were 
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42 N/m and 320 kHz, respectively. Firstly, the bioactive glass discs were polished in a 
similar way and immersed in culture medium and maintained at 37 °C for 24 hours. 
Then, the samples were allowed to completely dry for 48 h at room temperature. The 
images were recorded at room temperature and Gwyddion software was used to process 
the AFM images. The root mean square (RMS) surface microroughness was obtained 
on 30 x 30 m scans. 
Scanning electron microscopy (SEM). The surface roughness was qualitatively 
characterized by scanning electron microscopy (SEM) using FEI Inspect F50 available 
at LNNano, Campinas. The operating voltage and working distance were 20 kV and 
10.5 mm, respectively. The samples before and after immersion in culture medium were 
fixed on a metal stub using carbon tape and coated with gold before observations. 
In Vivo analysis.  Glass rods were implanted into rat tibia. For this, Brazilian 
College of Animal Experimentation (BCAE) guidelines were followed, and experiments 
were approved by Ethics Committee in Animal Use – ECAU/Unicamp (Protocol nº 
2777-1). Rods composed of BG45S5 or BGNS1 were implanted into a round defect 
created in the tibia of rats that had been anesthetized with a mixture of ketamine 
(ANASEDAN
®
) at 80 mg/kg and xylazine (DOPALEN
®
) at 10mg/kg. Five rats were 
used per group. A round transcortical defect was created using a spherical threfine bur 
(JET®) with a diameter of 2 mm after pulling aside the periosteum. The glass rod (4 
mm length × 2 mm diameter) was carefully introduced into the defect until total 
coupling, then the periosteum and the skin were sutured. After 28 days, the animals 
were euthanized, and the tibia was obtained from the animals and fixed for 24 h at 4 ºC 
in 10% zinc-buffered formalin (Sigma-Aldrich®). After fixation, they were decalcified 
in 5% EDTA (Synth Labsynth, Diadema, SP, Brazil), the glass rod was then carefully 
removed and the bones were paraffin-embedded and sectioned. 
Morphometry. All histological slides were stained with hematoxylin and eosin 
dyes and a light microscope (Nikon 80i model, Nikon Corporation, Tokyo, Japan) with 
a camera Nikon Model DS-Ri1 and NIS-Elements software: Advanced Research 3.0 
were used to quantify: (i) area of new-formed subperiostal bone and (ii) thickness of 
new-formed bone layer (for a fully detailed description of these analysis see 
Supplementary Information SI4) 
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Statistical Analysis. The comparison between means of subperiostal new formed 
bone and of the thickness of the bone layer formed around the implant were done 
through ANOVA one-way test with tukey (homogeneous variances) or Games-Howell 
(non-homogeneous variances) post-hoc. For all tests α= 0.05 was assumed. All data are 
described in mean and standard error. 
 
Supporting Information 
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Figure 10. ICP data: ion release vs. time in 50.69 mM HEPES solution at pH 
7.40 for BG45S5 and Nb-substituted bioactive glass. The data displayed in (a), (b), (c) 
and (d) are related to leached Na, Ca, Si, and P species from glass derived from 
substitution of P2O5 for Nb2O5. 
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Figure 11. ICP data: Nb ion release vs. time in 50.69 mM HEPES solution at pH 7.40 
for BG45S5 and Nb-substituted bioactive glass. The amounts of niobium determined by 
ICP-OES is consistent with the niobium content in each sample, i.e. BGSN5 exhibits a 
higher peak of niobium concentration compared to the BGSN1 bioglass. As expected, 
no niobium was detected for BG45S5. 
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Figure 12. 31P MAS-NMR spectra for the different glass compositions, recorded at a 
magnetic field strength of 9.4 T and a spinning speed of 10 kHz: (a) BG45S5, (b) 
BGSN1, (c) BGSN2.5, and (d) BGSN5. The chemical environmental for 31P shifts 
progressively evolves to lower values of δ, reaching a peak position similar to the 31P 
spectrum observed in the hydroxyapatite control. 
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Figure 13a. Micrographs of BM- derived MSCs treated for 72 h with culture media 
conditioned with the dissolution products of:  BG45S5 (c), BGSN1 (d), BGSN2.5 (e), 
and BGSN5 (f) at a concentration of 10 mg/mL. Following the incubation period, a 
negative control of dead cells was established by incubating cells with 70% methanol 
for 30 min (a). Cells treated with regular growth media served as a positive control (b). 
Dissolution products of none of the glass compositions were toxic to the tested cell line.  
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Figure 4b. Viability of bone-marrow-derived mesenchymal stem cells (BM-
MSCs) after 4 days of treatment with different glass-conditioned media measured by 
MTT assay. DMEM was used as a positive control and cells killed with DMSO as 
negative control. Results are expressed in mean and SEM. One-way ANOVA followed 
by Tukey‟s test was used to compare the groups. None of the glass-conditioned media 
(BG45S5, BGSN1, BGSN2.5 and BGSN5) reduced cell viability in comparison with 
the control group (DMEM). The group BGSN1 showed significantly higher absorbance 
than DMEM (p=0.0014) and BG45S5 (p<0.0001) after 4 days, suggesting superior cell 
proliferation. 
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Figure 5. Micrographs of calcium deposits within and around BM- derived MSCs 
stained with alizarin red (1%) and osteocalcin immunofluorescence after 21 days of 
treatment with different media. The six superior squares show micrographs (100× 
magnification) of BM-MSCs in which the red aggregates are calcium deposits. Cells 
treated with osteogenic medium (OST) showed a fully mineralized matrix which 
meaning that most cells were in a late stage of differentiation to osteoblasts. Those cells 
treated with BGSN1 and BGSN2.5 showed matrix mineralization.The four inferior 
squares display laser scanning confocal micrographs of BMMSCs treaded with BGSN1 
showing osteocalcin immunofluorescence (in red), cell nucleuses stained with DAPI (in 
bright blue), mineralized matrix by reflection of laser in TRANS mode (black) and an 
overlapping of matrix and nucleuses.  
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Figure 6. Three-dimensional surface AFM images for an area of 30 x 30 m and 
SEM micrographs at magnifications of 3000× of bioglass 45S5 (a) before and (b) after 
24 hours of immersion in complete culture medium; BGSN1 (c) before and (d) after 24 
hours of immersion in complete culture medium showing the increase of surface 
roughness. 
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Figure 7. Micrographs of transversal histological sections of rats‟ tibias treated 
with glass rods for 28 days and stained Haematoxilin and Eosin at 100 and 400 x 
magnification. The glass implants were removed after decalcification to allow the 
preparation of the histological sections (empty areas marked with “Glass” are where the 
glass rods were located for 28 days), but, some fragments of the glass can still be seen 
(red arrows). The micrographs show the bone layer (marked with “*”) that formed 
around the glass implant. Images A and B illustrate the group treated with BG45S5 
whilst images C and D represent rats treated with BGSN1. A t-student test showed no 
significant different between thickness of the bone layer formed in the rats treated with 
BGSN1 and the control group (BG45S5) (p=0.9568). For this analysis p<0.05 was 
considered. 
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Figure 8. Micrographs of transversal histological sections of rats‟ tibias treated 
with glass rods for 28 days and stained Haematoxilin and Eosin at 100 and 400 x 
magnifications. The glass implants were removed after decalcification to allow the 
preparation of the histological sections (empty areas marked with “Glass” are where the 
glass rods were located for 28 days). The micrographs show the formation of bone by 
the osteogenic cells present at the inner layer of the periosteum (marked with an “*”). 
The cement line (black arrows in images A and B) mark where the new bone started to 
form after the implantation of the material. Images A and B illustrate the group treated 
with BG45S5 whilst images C and D represent rats treated with BGSN1. A t-student 
test revealed that the group treated with BG45S5 (46469±804.5µm) presented a 
significantly larger sub periosteal bone area than the group treated with BGSN1 
(40615±1503µm) (P=0.0085). For this analysis p=0.05 was considered. 
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Table 1. Glass compositions of BG45S5 and Nb-substituted 45S5 bioglass. 
Glass 
 
SiO2 CaO Na2O P2O5 Nb2O5 
BG45S5 46,1 26,9 24,4 2,6 - 
BGSN1 45,1 26,9 24,4 2,6 1,0 
BGSN2.5 43,6 26,9 24,4 2,6 2,5 
BGSN5 41,1 26,9 24,4 2,6 5,0 
Table 2. 31P MAS NMR peak positions and full width half maxima (FWHM) 
for BG45S5, Nb-substituted 45S5 bioglass and commercial hydroxyapatite. 
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Nb-substituted silicate glass possesses enhanced osteoinductive properties. 
The replacement of 1 or 2.5 mol% of SiO2 with Nb2O5 in Bioglass® 45S5 significantly 
enhances cell proliferation after four days of treatment. BM-derived MSCs differentiate 
into osteoblasts in 21 days. Glass rods composed by Nb-containing glass enable bone 
growth onto its surface and release ionic products that promote subperioestal bone 
formation. 
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Supplementary Information 1. Ion release in 50.69 mM HEPES solution at pH 
7.40 for BG45S5 and Nb-substituted bioactive glass 
 
 
Figure SI1. ICP data: ion release as a function of square root of time in 50.69 mM 
HEPES solution at pH 7.40 for BG45S5 and Nb-substituted bioactive glass. The data 
displayed in (a), (b), (c), and (d) are related to leached of Na, Ca, Si, and P species, 
respectively, from glass derived from substitution of P2O5 by Nb2O5. Lines are linear 
regression of dissolution data up to 120 min. 
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Supplementary Information 2. Preparation of SBF solution 
The acellular simulated body fluid (SBF) solution was prepared with 
concentrations of ions equal to those of blood plasma, including 〖Cl〗^- and 〖HCO
〗_3^-. The pH value of 7.40 was obtained using the Hepes buffer at concentration 
50.69 mmol/L. Details about the concentrations of the ions present in the SBF solution 
is presented in Table SI2. 
 
Table SI2. Nominal ion concentrations of the SBF in comparison with those of human 
blood plasma. 
 
 
 
 
 
 
Supplementary Information 3. Glass rods preparation 
Ions 
Concentration/mM 
Blood Plasma SBF 
Na
+
 142.0 142.0 
K
+
 5.0 5.0 
Mg
2+
 1.5 1.5 
Ca
2+
 2.5 2.5 
Cl
-
 103.0 103.0 
HCO3
2-
 27.0 27.0 
HPO4
2-
 1.0 1.0 
SO4
2-
 0.5 0.5 
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Figure SI3. Devices used for the preparation of glass rods for in vivo tests: 
Graphite mould and suction system to force filling of the glass in the graphite mould. 
The vacuum pump was used to suction the molten glass, overcoming the high surface 
tension of the melt and allowing it to fill the 2 mm diameter graphite mould. 
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Supplementary Information 4. Histomorphometry  
 
Area of newly-formed subperiosteal bone 
 
 
Figure SI4.1. Micrographs showing H&E stained histological sections of rat tibia 
tissues at 40×, 100×, 200×, and 400× magnifications and quantification of the area of 
newly-formed subperiostal bone. The area of the newly-formed subperiostal bone was 
measured in one field of each side of the cortical defect, directly underneath the 
periosteum and adjacent to where the glass rod was previously located at 400× 
magnification. Five non-consecutive histological sections were analyzed per animal. 
Five rats were used per group (n = 5 per group). Thus, the mean and the standard error 
of the mean were recorded and further compared. 
(a)
(c) (d)
(b)
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Thickness of newly-formed bone layer 
 
Figure SI4.2. Micrographs showing H&E stained histological sections of rat tibia at 
40×, 100×, 200×, and 400× magnifications. Measurement of the thickness of newly-
formed bone layer that formed around the implant was repeated 20 times, and all 
measurements were performed at 400× magnification. Five rats were used per group (n 
= 5 per group). The mean and the standard error of the mean were recorded and further 
compared. 
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Abstract  
 
Introduction: The development of safe biomaterials for the treatment of large 
bone defects and non-unions is still challenging. Objective: We aimed to test the 
biocompatibility and bioactive properties of a bioactive glass containing niobium 
dioxide (Nb2O5) for bone replacement application. Materials and Methods: Glass 
biocompatibility was tested by in vitro and in vivo experiments. In vitro study consisted 
of assessing the cytocompatibility of Nb-doped glass with bone-marrow-derived 
mesenchymal stem cells (BM-MSCs). Systemic biocompatibility was verified by means 
of the quantification of biochemical markers and histopathology of liver (TGO/AST, 
TGP/ALT), kidneys (creatinine), and muscles (total CK). The glass genotoxicity was 
tested by the micronucleus test. The regeneration of a calvarial defect using was 
assessed using both qualitative and quantitative analysis of 3D microcomputed 
tomography images. Results: The Nb-doped glass was not cytotoxic to BM- derived 
MSCs. It is systemically biocompatible causing no signs of damage to high metabolic 
and excretory organs such as liver and kidneys. No mutagenic potential was observed in 
the micronucleus test. MicroCT images showed Nb-containing glass was able to nearly 
fully regenerate a critical-sized calvarial defect and was far superior to standard 45S5 
Bioglass®. Defects filled with Nb doped bioglass showed over 90% coverage compare 
to just 66% for 45S5 Bioglass®. For one animal the defect was completely filled in 8 
weeks. Conclusion: Taken together these results make clear that Nb-containing 
bioactive glass is a safe and effective biomaterial for bone replacement. 
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1.0 Introduction 
 
Bone fractures are the most widespread large- organ traumatic injury that affects 
humans
1
. The regeneration process after fractures normally achieves a successful 
healing outcome yet up to 10–15% of the patients show an impaired healing, delaying 
the process or even leading to a non-union
2
. Fractures represent not only a burden for 
the patient‟s life, but the costs with surgery and hospitalization also constitutes a 
considerable cost for socio- economic and health care systems
2
. In fact, it has been 
reported that the treatment of an established non- union of a bone costs over $10,000 on 
average
2
. The estimated number of fractures for the year 2000 was 9.0 million 
worldwide, but, as some fractures cause disability for a period longer than 1 year this 
number was estimated at approximately 50 million
3
. This high number of fractures 
stimulates the development of synthetic materials for bone replacement. 
In 1971 the researcher Larry Hench developed the first bioactive material, the 
Bioglass® 45S5 
4
. This material is a glass composed of 46.1 mol. % SiO2, 24.4 mol.% 
Na2O, 26.9 mol.% CaO and 2.6 mol.% P2O5
5
. By means of ion exchange with the body 
fluids, Bioglass®45S5 spontaneously forms a layer of hydroxyl carbonate apatite 
(Ca5(PO4)3OH) (HCA) on its surface, which is the main inorganic component of bone
6
. 
Due to its micro-/nano-scale complexity the HCA layer gives support to osteogenic 
cells to attach, spread and produce mineralized bone matrix whilst the biomaterial 
slowly dissolves until it be completely substituted by the new-formed bone
5–7
. Seeking 
to improve the mechanical and biological properties of Bioglass®45S5 many variations 
of the original composition have been designed and investigated
6
.  
The incorporation of niobium into biomaterials appears to be an interesting 
approach to improve their mechanical and biological properties
8–18
. Niobium is of 
interest for biomedical applications and has been incorporated into metallic alloys for 
dental implants where it imparts superior corrosion resistance, low cytotoxicity, and 
enhanced wear resistance 
13
.  Furthermore, some investigations reported that sol–gel-
derived niobium oxide gels promote apatite formation within a week of immersion in 
simulated body fluid which indicates that this element is a good candidate for bioactive 
glass for bone replacement
19,20
. Niobium has already been incorporated into calcium 
phosphate invert glasses Containing 
9
 and in fluorapatite glass-ceramics
20
 showing great 
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biocompatibility and also stimulating osteogenic differentiation of human mesenchymal 
stem cells (MSCs) and maturation of Mouse osteoblast-like cells (MC3T3- E1 cell) by 
means of direct contact
20
 or through its ionic dissolution products
9
. Nb doped glasses 
are also reported into increase vascularization
21
. However, despite its great potential for 
biomedical applications niobium has rarely been incorporated in silicon-rich bioactive 
glass such as Bioglass®45S5. In view of that, we altered that composition of the 
original Bioglass®45S5 replacing all content of P2O5 (2.6 mol %) with Nb2O5 and 
investigated the biocompatibility, genotoxicity and the potential for osteointegration of 
this new Nb-containing glass. The biocompatibility of Nb-containing glass was tested 
by in vitro and in vivo experiments. The in vitro approach consisted of assessing the 
cytocompatibility of Nb-doped glass with Normal Human Osteoblasts (NhOsts) by 
quantitative MTT analysis and qualitative Live/Dead assay. Systemic biocompatibility 
was verified by means of quantification of biochemical markers of hepatic (TGO, TGP, 
and GamaGT), renal (creatinine and urea), and cardiac damage (total CK). In addition, 
histological sections of liver and kidneys were examined for any sign cellular or tissular 
damage. The glass genotoxic potential was tested by the micronucleus test. The 
regeneration of a 5mm sized calvarial defect was examined by means of both qualitative 
and quantative analysis of 3D microcomputed tomography images. 
2.0 Materials and Methods 
 
2.1 Preparation of bioactive glasses and conditioned cell culture 
media 
We tested a variation of melt-quench derived Bioglass® 45S5, 
(SiO2)46.1(CaO)26.9(Na2O)24.4(P2O5)2.6. In this variation 2.6 mol% of P2O5 were replaced 
by 2.6 mol% of niobium dioxide (Nb2O5), resulting the composition named BGPN2.6. 
The glass was prepared by thoroughly mixing the precursors oxides SiO2 (Alfa Aesar, 
99.5%), CaCO3 (Alfa Aesar, 99.95-100.5%), Na2CO3 (Sigma-Aldrich, ≥99.5%), 
NH4H2PO4 (Sigma-Aldrich, ≥99.5%), and Nb2O5 (Sigma-Aldrich,≥99.99%). The 
batches were melted at 1400ºC for 90 minutes in platinum crucibles. The melt was then 
poured into graphite mould which had been preheated to 370 °C and annealed at this 
temperature overnight before being allowed to cool slowly to room temperature. After 
cooling down the glasses were ground to powder. The particle size was standardized 
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between 40 and 60 µm using a series of micro sieves. For the experiments with the cells 
glass- conditioned media were prepared. For this, powders of BGPN2.6 and BG45S5 
were added to cell culture medium (DMEM/F12) at a concentration of 10µg/ml, mixed 
for 24 hours and filtered using an ultrafine filter (0.22µm pore size) and the media were 
left within the cell incubator for 4 hours (time necessary for pH buffering, as observed 
in the results of the experiment described in the item 2.3). 
 
2.3 Determining pH behaviour of culture media containing 
bioactive glasses prior cell treatment 
Cell culture medium has bicarbonate ions in its composition. These ions react 
with CO2 in the cell incubator buffering the medium, maintaining pH in an ideal level 
for cells. Glass dissolution affects the pH of the medium, usually increasing it, and pH 
directly influences cell behaviour. However it is known that the body naturally buffers 
the pH
22
. In view of this, we studied the kinetics of media buffering in the cell incubator 
over time in order to determine how much time would be necessary for neutralizing 
their pH before adding the cells. For this, 500µl of each medium were added to each 
well of a 24-well plate, in duplicate. The pH was measured prior incubation and after 
increasing time intervals up to 72 hours.  
 
2.4 Cell Culture 
Normal Human Osteoblasts (NhOsts, Lonza, Walkersville, MD) were cultured 
in growth medium (Osteoblast Growth Medium Bullet Kit, Lonza, Walkersville, MD). 
Cell flasks were kept in incubator at 37ºC in an atmosphere of 5% of CO2. The culture 
medium was changed every other day. All procedures using osteoblasts were carried out 
following the manufacturer‟s protocol.   
2.5 MTT 
Cell culture media conditioned with BG45S5 and BGPN2.6 were used to treat 
3000 NhOsts for 72 hours. A positive control group of NhOsts was treated with growth 
medium. A negative control group of cells were killed by incubation in ETOPOSIDE.  
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MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) is a soluble 
tetrazole salt in water that produces an yellowish solution when prepared in culture 
medium or in saline without phenol red. When dissolved, MTT is converted into 
insoluble purple formazan through the cleavage of the tetrazole ring by dehydrogenases. 
This insoluble formazan was solubilized using Dimethyl Sulfoxide (DMSO). The 
dissolved material was spectroscopically quantified as it produces an absorbance that is 
proportional to the concentration of the converted dye. 
To quantify cell viability we followed manufacturer‟s protocol. Briefly, 10µl of 
MTT (stock solution at the concentration of 5mg/ml) were added to each well 
(containing 100µl of phenol red-free culture medium) incubating for 4 hours in the cell 
incubator at 37°C and 5% CO2. After the incubation time the formed formazan was 
solubilized with DMSO incubating it for 10 minutes. The absorbance of the converted 
formazan was measured at the wavelength of 570nm.  
 
2.6 Live/dead assay 
For this assay cells were treated with the same media described for the MTT 
assay (Control, BG45S5, BGPN2.6, and ETOPOSIDE), following the same conditions 
and timeframe (72 hours). In this assay live cells are distinguished by ubiquitous 
intracellular esterase activity, which is determined by enzymatic convertion of the 
virtually nonfluorescent cell-permeant calcein AM to the intensely fluorescent calcein. 
Calcein is retained within live cell‟s cytoplasm, producing an intense green fluorescence 
(~495nm)
23
.   
EthD-1 enters cells with damaged membranes and undergoes a 40-fold 
enhancement of fluorescence upon binding to nucleic acids, thereby producing a bright 
red fluorescence in dead cells (ex/em ~495 nm/~635 nm). EthD-1 is excluded by the 
intact plasma membrane of live cells
23
. For this assay all procedures were carried out on 
human osteoblasts following the instructions of the manufacturer (ThermoFisher-
Scientific®).  
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2.7 Animals 
We used 90 adult rats weighing between 350 and 460 g provided by the Central 
Bioterium of UNICAMP (CEMIB).  The rats were maintained in the Bioterium of the 
Department of Anatomy, in the Institute of Biology (IB), UNICAMP. They stayed in 
standard boxes in controlled environmental conditions (12 hours‟ bright/dark cycles) 
with standard food and water.  
Table 1 shows the sample size of the experimental groups and subgroups. All 
experimental protocols are in accordance with the ethical principles for animal 
experimentation adopted by the Brazilian College of Animal Experimentation 
(COBEA) and were approved by the Committee for Ethics in Animal Use of the 
University of Campinas – CEUA/UNICAMP (Protocol Number: 3467-1). 
 
Table 1. Sample division into the different experimental groups  
 
 Number of rats 
Material 14 days 28 days 56 days 
Control 6 6 6 
Sham 6 6 6 
BG45S5 6 6 6 
BGPN2.6 6 6 6 
Total: 72 rats 
 
 
2.8 Surgical Procedure: 
Before the surgery animals were weighed and transferred into individual boxes. 
A pre-anaesthetic dose of Tramadol (TRAMAL® - RETARD) (5mg/kg) was applied 15 
minutes before the injection of anaesthetics. Animals were anaesthetized by means of an 
intraperitoneal injection of a mixture of Xilazin (Xilazin – Syntec) (0,3mg/kg/weight) 
and ketamine hydrochloride (0,8mg/kg/weight). A prophylactic dose of 1mg/kg/weight 
of Enrofloxacin (Biofloxacin – Biovet) was applied to prevent bacterial contamination. 
The full description and photos of the surgical technique can be found in figure 7.  
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Figure 2. Development of a critical size calvarial defect in rat: a. an incision was 
made starting at the nose bridge, and ending at the base of the skull, using a scalpel. b. 
Skin, subcutaneous tissue, temporal muscle, and the periosteum were pulled aside for 
complete exposure of the parietal bones. c. 5 mm round full-thickness calvarial defect 
was created in the parietal bone with a 5 mm-diameter tissue punch (Richter®). d. In the 
control group, the defect was left empty, in the other groups it was filled with different 
glass compositions (in powder form). e. The periosteum was sutured using a 6-0 Nylon 
non-absorbent monofilament (ETHILON®). f. The skin was sutured using a 4-0 Nylon 
non-absorbent monofilament (ETHILON®). In the SHAM group the periosteum and 
skin were sutured immediately after step “b”, without making the bone defect.  
2.9 Systemic Toxicity  
After the experimental time (14, 28 or 56 postoperative days) rats were 
euthanized and their blood, liver, and kidneys were collected. The specimens of liver 
and kidneys were fixed with Bouin solution for 24 hours and embedded in paraplast 
(Sigma-Aldrich®). All paraffin-embedded histological sections were stained using 
Hematoxilyn and Eosin and histopathologically examined under a light microscope. 
Systemic toxicity was also analysed by the quantification of biochemical toxicological 
markers from kidneys (Creatinine), liver (TGO, TGP) and muscles (Total Creatine 
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Kinase – Total CK). The markers were quantified by means of enzymatic kits 
(Interkit®).  
 
2.10 Micronucleus test 
Micronucleus induction is a key characteristic of genotoxic compounds and the 
analysis of micronuclei formation resulting from DNA strand breakage (clastogens) or 
interference with chromosome segregation (aneugens) is an important component of 
toxicology screening of new biomaterials. For this assay, we collected bone marrow 
from rat‟s femur using a disposable syringe containing 1 mL of 0.9% saline at room 
temperature. The harvested bone marrow was transferred to a sterile tube, homogenized 
and centrifuged for 10 minutes at 900 rpm and part of its supernatant was discarded.  
The sediment was re-suspended in the remaining supernatant. One drop of this 
bone marrow suspension was placed on one extremity of a microscope slide. Using 
another glass slide a smear was made and left to dry at room temperature. The dry slides 
were fixed in 100% methanol for 10 minutes and dried at room temperature. Once fixed, 
the slides were stained with Giemsa diluted in Sorensen buffer (Na2HPO4 0,06M e 
KH2PO4 0,06M – pH 6,8), at the proportion of 1 mL of Giemsa for 20 mL of buffer 
solution for 10 minutes, washed with distilled water, and dried at room temperature. 
Entellan® was used to mount the histological slides that were further analysed.  
For the calculation of the relative number of micronucleus 3000 erythrocytes 
were counted per animal in five animals per group (BG45S5, BGPN2.6 and SHAM). 
The means of micronucleus were compared to the SHAM group.   
 
2.11 Computed Microtomography of rats’ calvaria.  
Immediately after the euthanasia, the calvarias were dissected and fixed with 10% 
buffered formaldehyde for 24 hours and kept in 70% ethanol up to the analysis. Prior to 
the microcomputed tomography scanning specimens were left to dry at room 
temperature for at least 60 minutes. We scanned 5 calvarias per group. Scanning was 
performed using SkyScan 1278 with 84.6 µm of pixel size, 53kV, 0.5 mm of Al filter 
and 0.18° of rotation. For the image reconstruction a correction of 10% of Beam 
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Hardening was applied together with a ring artefact correction of 5 and Gaussian 
smoothing of zero. The amount of bone formed within the defect was calculated as a 
percentage of the total volume of a pre-determined volume of interest and normalized 
by the mean values of the SHAM group (which represented 100%). The amount of bone 
found in the control group served as a blank that was subtracted from the other values. 
3.0 Results 
 
3.1 pH behaviour in culture media containing bioactive glasses 
It is known that pH is a variable that significantly affects cell behaviour. For the 
cell culture experiments we decided to remove this variable in order to investigate the 
precise role of the ionic products derived from glass dissolution. For this, we studied the 
kinetics of media buffering in the cell incubator over time to determine how long it 
would take to neutralize media‟s pH.  
We observed that all glass compositions caused an increase in pHand this is 
attributedto the release of positively charged ions such as Ca
2+
 and Na
+
from the glass 
into the cell medium. After 24 hours mixing the different glass compositions in media at 
a concentration of 10 mg/ml we measured their pH. The pH reached 10.27 in the 
medium conditioned with BG45S5 and 9.46 in the group BGPN2.6 (Figure 2). No glass 
was added to the control group (growth medium) and osteogenic group (osteogenic 
medium) and their pHs were 7.77 and 8.22 respectively.  
Cell culture medium containing living cells tends to become acidic over time due to 
normal cell metabolism reactions. The chemical reaction between HCO3
- 
present in the 
cell medium and the CO2
 
present in the cell incubator is responsible for buffering the 
system maintaining medium‟s pH around 7.4-8.0 which is suitable for living mammals 
cells. We observed that it takes 4 hours inside the incubator for the media‟s pH to reach 
physiological levels (Figure 1). Thus, to exclude pH as a variable all media were left to 
buffer in cell incubator for 4 hours prior being used to treat cells as it is wekll known 
that the body will naturally buffer the pH. 
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Figure 3. pH variation of different culture media along 8 h of incubation at 37ºC 
and 5% CO2. It takes 4 hours inside the cell incubator for the media‟s pH to reach 
physiological levels (7.4 – 8.0). 
3.3 Viability of bone-marrow-derived MSCs 
The survival of Normal Human Osteoblasts (NhOsts) within the different media 
over 72 hours was assessed using MTT and Live/Dead assay. It can be seen in figure 4 
that none of the glass-conditioned media were cytotoxic to the cells. It proves that the 
addition of niobium dioxide (Nb2O5) did not compromise the cytocompatibility of 
BG45S5 and can replace phosphorous pentoxide (P2O5) without damaging living cells 
(Figure 3). 
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Figure 4. Viability of Normal human Osteoblasts (NhOsts) after 72 hours of 
treatment with Control Medium (A), BG45S5 (B), BGPN2.6 (C), and  ETOPOSIDE 
(D). None of the glass conditioned media was cytotoxic to the human osteoblasts. 
Quantification of MTT assay displaying the absorbance as % of the control group. No 
significant difference was observed between groups treated with glass- conditioned 
media and the control group (ns bars). All groups showed significantly higher viability 
than the negative control group (*). Live/Dead assay photomicroscopies of NhOsts 
treated with the different media for 72 hours (100 x magnification). Living cells appear 
in bright green whereas the dead cells appear in red. 
3.4 Systemic Biocompatibility 
3.4.1 Biochemical Markers 
In all groups the levels of TGO/AST, TGP/ALT and were similar to those of the 
control and SHAM groups (Figure 3, upper row). This result shows that the presence of 
implants did not cause any kind of damage to the hepatic cells. Results of the levels of 
renal (Creatinine) and cardiac (Total CK) biochemical markers support the claim that 
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these materials are biocompatible as none of them showed significant difference 
between the glass-treated rats and those from the control and SHAM groups (Figure 3, 
bottom row). 
 
Figure 5. Concentration of biochemical markers of hepatic, renal and muscular 
damage after 56 postoperative days. Data are displayed as mean and SEM. One- way 
ANOVA and Tukey‟s post-test were performed to compare the experimental groups 
(BG45S5 and BGPN2.6) to SHAM group. No significant difference was found between 
treatment groups and SHAM group. This result reveals that none of the glass 
compositions were toxic to these three organs. 
3.4.2 Histopathology 
 
Histological sections of liver and kidneys were stained with Haematoxylin and 
Eosin and were qualitatively analysed. We looked for any sign of tissue damage or 
cellular disturbance. A thorough examination of the organs confirmed the results for the 
biochemical markers. After 56 postoperative days no organ showed any noticeable sign 
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of damage (Figure 5). In the livers all hepatocytes presented normal morphology as did 
the hepatic parenchyma, showing no aggregates of connective tissue or any 
inflammatory cell which could be sign of toxicity (Figure 5, upper row). In the kidneys, 
their functional units, the glomerulus appeared normal as well as the proximal and distal 
convoluted tubules (Figure 5, bottom row). Just as in the liver, no sign of inflammation 
or tissue damage was observed in any group attesting the integrity of the kidneys.   
 
 
Figure 6. Photomicrographies of histological sections of liver (upper row) and 
kidneys (lower row) after 56 postoperative days. Magnification 200 x. Haematoxylin 
and Eosin staining. No signs of damage were observed in any of the analyzed organs. 
None of the glass compositions were toxic to these organs. 
3.4.3 Mutagenic Potential 
 
The carcinogenic risk of Nb-containing glass was tested by means of the 
micronucleus test (MN) which is a method for to assess chromosomal damage in cells 
exposed to genotoxic agents. We counted 3000 erythrocytes per animal and compared 
the mean of each group with the SHAM group. The SHAM group exhibited, on 
average, 1.87 micronucleus in a thousand erythrocytes. No significant difference was 
observed between the experimental groups and the SHAM group (Figure 6). This result 
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reveals that none of the glass compositions are genetically toxic and display no 
mutagenic potential. 
 
Figure 7. Number of micronuclei per 3000 erythrocytes. Data are displayed as mean 
and SEM. One- way ANOVA and Tukey‟s post-test were performed to compare the 
experimental groups (BG45S5 and BGPN2.6) with SHAM. No significant difference 
was found between the experimental groups and the SHAM group (p=0.0863). This 
result shows that none of the glass compositions possesses mutagenic potential. 
3.5 MicroCTs of rat calvaria 
The regeneration of a 5 mm calvarial defect was assessed by means of 
microcomputed tomography (microCT). This analysis is a powerful tool for the 
evaluation of bone tissue because it provides access to the 3D microarchitecture of the 
bone. In the present work the qualitative and quantitative microCT analysis of the rat`s 
calvarias were performed ex vivo. MicroCT images showed that the calvarial defect 
maintained its size even 56 days after surgery in the control group, proving to be a 
critical-sized defect. The treatment with BG45S5, on average, filled 65.63% of the bone 
defect whereas BGPN2.6 filled 91.66% of the defect, on average. In one rat BGPN2.6 
completely filled the defect (figure 7).  
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Figure 8. 3D reconstructions of microcomputed tomography images of rats‟ 
calvarias of the three experimental groups (Upper row). Tranversal sections of the 
calvarial defect of the three experimental groups. Imagens taken after 56 postoperative 
days using SkyScan 1278. Almost no bone formation can be observed in the control 
group after 56 days. The group treated with BG45S5 showed a good amount of bone 
within the defect yet not enough to completely fill it. The composition BGPN2.6 was 
the only one that was able to completely fill the 5 mm calvarial defect after 56 days in 
one of the subjects.   
4.0 Discussion 
 
We performed both in vitro and in vivo analysis in order to verify the biological 
properties of Nb-cointaining bioactive glass. The glass showed great biocompatibility as 
it was compatible with normal Human Osteoblasts (NhOsts) in the in vitro assay and in 
the in vivo experiments it did not compromise high metabolic and excretory organs such 
as liver and kidneys along 8 weeks. Through microcomputed tomography we observed 
that Nb-containing glass was capable of stimulating the regeneration of a 5-mm 
calvarial defect in 56 days.  
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When implanted into the body a biomaterial for bone replacement must be 
gentle to its surrounding cells in order to enable efficient osteointegration. Previous 
reports demonstrated the cytocompatibity of niobium in some other types of 
biomaterials with several types of cells. Pure niobium discs were shown to be 
cytocompatible with mesenchymal stem cells derived from human bone marrow 
(hBMSCs) seeded and grown onto its surface up to 10 days
8
. Cells adhered well to the 
surface of pure-niobium discs presenting a spread morphology which is an evidence that 
they were active
8
.  Mesenchymal stem cells were also observed to attach and proliferate 
well onto niobium-doped fluorapatite glass-ceramics. The dissolution products of Nb-
doped glass-ceramic were also shown to stimulate greater osteogenic differentiation of 
hMSCs when mixed with osteogenic medium
10
. Pure metalic Nb also proved to be 
bioinert when implanted into rats for 4 weeks
24
.  
Despite the cytocompatibility which is a good sign of non-toxicity we also need 
to take into account the fact that the implant will progressively dissolve and be replaced 
by living tissue. Part of its dissolution products and even microscopic particles get into 
the blood stream and may end up in high metabolic and excretory organs such as liver 
and kidneys. This is the first time organs have been studied to test the systemic behavior 
of these materials to ensure that no damage was caused by the dissolution products of 
Nb-containing glass after 8 weeks (Figures 3 and 4). These results are in accordance 
with an investigation in which Swiss male mice were treated with a single dose (1 mL) 
of 3 % niobium oxide (Nb2O5) diluted in phosphate-buffered saline (PBS), 
intraperitoneally (i.p.). In this cited study rats hepatocytes showed some signs of 
degeneration between the third and seventh day after the intraperitoneal application. 
However, after 12 days all livers appeared regenerate with cellular mitoses
25
. In our 
investigation we did not observe signs of degeneration nor regeneration at any of the 
studied time points. We believe that in the aforesaid investigation they might have 
provoked a mild hepatic degeneration due to the direct intraperitoneal injection of a 
higher dose of Nb2O5 (~30µg per rat) than ours (~3.4 µg per rat).  
The assessment of the genotoxic potential of new biomaterials is imperative. In 
order to evaluate the genotixicity of Nb-containing glass we performed micronuclei 
analysis (MA). This is considered to be one of the gold-standard analyses for the 
recognition of the mutagenic potential of any treatment. In the present study 3000 
eritrocytes were taken into account per animal and the number of microcunclei found 
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was compared to the SHAM group (group in which no fracture nor treatment was 
performed). Nb-doped glass showed no sign of genotoxicity demonstrating that, at least 
in this particular dose, niobium is a safe metal to be used in biomaterials. Other metallic 
ions have been shown to possess genotoxic effects. Vanadium, one of the components 
of the titanium alloy (Ti-6Al-4V), a well-recognized primary metallic biomaterial for 
orthopedic implants, can generate long-term health problems such as peripheral 
neuropathy, osteomalacia and Alzheimers disease
26
. Furthermore, lanthalum and nickel 
were shown to cause some degree of DNA damage
27,28
. Therefore, Nb-containing glass 
appears to be a safe biomaterial that causes no cellular or DNA damage being a very 
interesting candidate for use in biomedical devices for bone replacement.  
The osteoestimulative capacity of Nb-containing glass was tested by treating 
critical-sized calvarial defect for up to 8 weeks. A critical size defect is defined as “the 
smallest size tissue defect that will not completely heal over the natural lifetime of an 
animal”29. For the rat calvarial defect, 8 mm is generally accepted to be of critical size30. 
Nevertheless, we chose to work with 5 mm size defect because it can be made in one 
rat‟s parietal bone without crossing the sagittal suture. The sutures are nearly 
immovable fibrous joints that connect two or more bones. In the case of the sagittal 
suture it connects the two parietal bones. It is important to take into account the fact that 
fibrous joints (such as the sagittal suture) show a very different pattern of regeneration 
from flat bones (such as parietal bones). In view of this, we believe the occurrence of 
these two different rates of regeneration at the fracture site might constitute an extra 
variable that could confuse the interpretation of the results as the bioactive glass may 
interact with these two tissues in different ways. Furthermore, even though our 5 mm 
size calvarial defect showed very low regeneration along 8 weeks, to avoid any 
influence of such regeneration over the results the mean value of the control group 
(empty defect) served as a blank that was subtracted from the means of all other groups.  
The analysis of MicroCT images showed that treating circular calvarial defect 
with Nb-doped glass promoted great fulfillment after 8 postoperative weeks revealing 
the great osteostimulative capacity of this glass (Figure 6). Our study is the first one to 
report osteostimulative effects of Nb-containing bioactive glass using critical-sized 
calvarial defect. Two other studies investigated the osteintegrative properties of other 
types of Nb-containing biomaterials
8,13
. Wang at al. implanted Ti–Nb–Zr–Ta–Si alloy 
into rabbit‟s femur to assess its mineral apposition rate and bone-implant contact13. The 
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authors concluded that Ti–Nb–Zr–Ta–Si alloy showed significantly higher mineral 
apposition rate compared to CpTi implants after 4 postoperative weeks and showed no 
difference in bone-implant contact (BIC). They suggested that Ti–Nb–Zr–Ta–Si alloy 
had favorable biocompatibility and had an effect on the promotion of osteogenesis
13
. 
Furthermore, Bartolomé and colleagues verified the biological tolerance of new 
zirconia/Nb biocermets implants in rabbit‟s tibias. Their results showed effectiveness of 
osseointegration after 6 postoperative months as new bone was observed around the 
implants at retrieval date
8
. Together these results indicate that the presence of niobium 
in the bulk of biomaterials seems to improve material‟s biocompatibility and increases 
bioactive properties such as osteoconduction and osteostimulation.  
It is important to considerate that the calvarial defect serves as a model for 
intramembranous bone formation and thus may be less applicable to biomaterials or 
strategies for endochondral bone formation
30
; thus, this result may be applicable mainly 
for large fractures in flat bones such as those of the skull, ribs, pelvis and some parts of 
the vertebras. 
5.0 Conclusion 
 
In summary we conclude that the Nb-containing glass BGPN2.6 is not cytotoxic 
to Human Osteoblasts. Its biocompatibility was confirmed by the results of the in vivo 
experiments that showed the material does not cause any harm to high metabolic and 
excretory organs such as liver and kidneys. Moreover, the Nb-containing glass does not 
show any genetic toxicity, therefore can be used without risk of mutagenicity. These 
results attest this glass composition is biocompatible and, up to the used concentration, 
can be implanted into the body without any harm. Microcomputed tomography 
demonstrated that Nb-doped glasses stimulated the regeneration of a large calvarial 
defect and the results showed a 40% increase in defect repair compared to 45S5 
bioglass. Taken together these results support the claim that Nb-containing bioactive 
glass is a safe and efficient biomaterial that can be used for bone replacement.  
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PART TWO: THE DEVELOPMENT AND CHARACTERISATION 
OF GALLIUM DOPED BIOACTIVE GLASSES FOR POTENTIAL 
BONE CANCER APPLICATIONS  
Objectives of this study 
In this study, we have developed a series of novel gallium oxide doped bioactive 
glasses to specifically target osteosarcoma cells whilst aiding new bone formation. The 
methods and results of this study are described in the following scientific paper: 
Article 4: The development and characterisation of gallium doped bioactive 
glasses for potential bone cancer applications. (Published in the journal: ACS 
Biomaterials Science & Engineering. DOI: 10.1021/acsbiomaterials.7b00283)  
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ABSTRACT 
In this study we have developed a series of novel gallium oxide doped bioactive 
glasses to specifically target osteosarcoma cells whilst aiding new bone formation. The 
results show that osteosarcoma (Saos-2) cell death is induced through the addition of 
gallium oxide. Relative to the gallium-free control glass (0% Ga) glasses containing 1, 2 
and 3% Ga decreased Saos-2 cell viability in a dose dependant manner. After 72 hours 
in media preconditioned with 3% Ga Saos-2 cell viability was reduced by over 50%. 
Corresponding studies undertaken on primary normal human osteoblast cells (NHOst) 
demonstrated no adverse effects to the gallium containing glasses.  Hydroxyapatite 
formation was observed for all glasses when exposed to simulated body fluid. 
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INTRODUCTION 
Survival for osteosarcoma patients is poor despite the aggressive use of surgery, 
chemotherapy, and/or radiotherapy
1
. Therefore, to improve the clinical outcome safe 
and effective therapeutic materials are required. The minimum key requirements for an 
effective biomaterial targeted towards osteosarcoma therapy are (1) to successfully 
eradicate any residual tumour not excised during the surgery without being cytotoxic to 
the surrounding tissue and (2) to provide a suitable platform for the regeneration of new 
bone. A potential solution to this problem is to engineer materials capable of replacing 
damaged tissue whilst simultaneously preventing reoccurrence and/ or metastases of 
tumours after surgery. The development of synthetic alternatives that help regenerate 
bone by acting as active temporary scaffolds is associated with considerable research 
activity. However there have been very few reports of synergistic scaffolds which can 
help manage cancer and simultaneously promote wound healing. 
Bioactive glasses are one of the most promising bone replacement/ regeneration 
materials because they bond to existing bone, are degradable and can stimulate new 
bone growth by the action of their dissolution products on cells
2,3
. Bioglass
®
, 
(SiO2)46.1(CaO)26.9(Na2O)24.4(P2O5)2.6,  exhibits class A bioactivity meaning it bonds to 
bone and stimulates new bone growth even away from the glass–bone interface4-6. 
Direct comparisons with hydroxyapatite in vivo have shown that 45S5 Bioglass
®
 forms 
a more rapid and stronger bond with bone
7,8
. Bioglass
®
 was originally developed to 
provide a controlled release of calcium and phosphorous ions under physiological 
conditions
5
. The calcium and phosphorous ions precipitate into amorphous calcium 
phosphate which then crystallises into hydroxyapatite to form new bone mineral
9-11
. 
Bioglass
®
 has received FDA approval and has been in clinical use since 1985. Whilst 
there has been considerable interest in developing and optimising bioactive glasses for 
bone regeneration little or no research has been undertaken on bioactive glasses 
specifically for bone cancer applications.  
Gallium (Ga) is the most widely used metal ion for cancer treatment with the 
exception of platinum
14
. Gallium has the ability to localise in tumour cells via surface 
transferrin receptors
15. Based on its clinical efficacy, gallium nitrate (Ganite™) is used 
as a treatment for cancer-associated hypercalcaemia
16
. Furthermore, gallium nitrate has 
been shown to inhibit increased bone turnover and to decrease osteolysis in patients 
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with bone metastases from a variety of different cancers
16
. Bockman et al (1995)
17
 
demonstrated that administrating low, non-toxic doses of gallium nitrate to patients with 
Paget‟s disease of bone, a disease characterised by abnormal bone remodelling and 
increased bone resorption, rendered bone more resistant to resorption by blocking 
osteoclast function without affecting their viability. Several studies indicate that gallium 
nitrate may have an application in diseases associated with increased bone loss such as 
osteoporosis, multiple myeloma and bone metastases. Uptake of bioavailable gallium is 
however low when administered orally as a salt. The recommended mode of 
administration for gallium nitrate is therefore via a continuous intravenous infusion for 
5–7 days. However, this treatment is very inconvenient since patients receive this drug 
either intravenously in hospital or as an outpatient via a pump device. A scaffold that 
can provide a site specific controlled delivery of gallium would therefore be highly 
advantageous. Gallium ions have previously been incorporated into phosphate based 
glasses to deliver a controlled antimicrobial effect
18,19
. Wren et al. and Towler et al. 
incorporated Ga into bioactive glasses for bone cement applications and for 
antimicrobial functionality
20-22
. More recently, Frachini et al. and Lusvardi et al. have 
incorporated gallium oxide into bioactive glasses for antimicrobial applications
23,24
. 
However no studies have been undertaken on osteosarcoma cells. The present study 
therefore investigates the potential of incorporating gallium into bio-degradable 
bioactive glasses specifically targeted towards bone cancer applications. 
MATERIALS AND METHODS  
  Glass synthesis. Melt-quench derived 45S5 Bioglass, 
(SiO2)46.1(CaO)26.9(Na2O)24.4(P2O5)2.6, and the gallium doped analogues were prepared 
using SiO2 (Alfa Aesar, 99.5%), CaCO3 (Alfa Aesar, 99.95–100.5%) and Na2CO3 
(Sigma-Aldrich, ≥99.5%), NH4H2PO4 (Sigma-Aldrich, ≥99.5%), and Ga2O3 (Alfa 
Aesar, 99.99%)
25
. In brief, the precursors were weighed in the appropriate molar ratio to 
give (Ga2O3)X(SiO2)46.1-3X(CaO)26.9(Na2O)24.4(P2O5)2.6 where X=1, 2 and 3%. The 
compositions were carefully selected to maintain a network connectivity of 2.11 which 
exhibits optimal bioactivity (see supplementary section). Precursors were thoroughly 
mixed and placed into a 90% platinum - 10% rhodium crucible. The crucible was placed 
into a furnace at room temperature and heated at a rate of 10°C min
−1
 to 1450 °C and 
held at this temperature for 90 min. The melt was then poured into a graphite mould 
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which had been preheated to 370 °C and annealed at this temperature overnight before 
being allowed to cool slowly to room temperature.  
Glass discs were cut in discs using an IsoMet™ 1000 Precision Diamond Saw 
(Buehler). Discs, 10mm diameter and 2mm thick, were polished using a MetaServ® 
(Buehler) polishing machine to a finish of 0.06µm using colloidal silica. Glass particles 
were prepared using a planetary ball mill (PM100, Retsch) and the particles were sieved 
to give a size distribution between 40 to 60 microns. 
Hydroxyapatite formation. A simulated body fluid (SBF) solution was 
prepared using the method outlined by Saravanapavan and Hench 
26
. SBF emulates the 
salt ion concentrations found in human blood plasma and can be used to test for the 
formation of hydroxyapatite in vitro. The three gallium containing glasses 1%, 2% and 
3% together with the control glass (45S5) were placed in separate containers and 40 ml 
of SBF salt ion solution was added. The samples were sealed and maintained at 37 °C 
for 7 days. After reacting in SBF the samples were removed and rinsed with distilled 
water and acetone to remove any residual salts and halt reactions. Samples were dried at 
60 °C and then assessed for apatite formation using X-ray diffraction. 
X-ray diffraction experiments were conducted using a Bruker D8 
diffractometer operating at the copper kα wavelength of 1.54 Å. Finely powdered 
glasses were measured over a two theta range of 10 to 80° in 0.02° steps. Measurements 
were taken at one second per point and no smoothing was undertaken. 
Dissolution. Stock solutions of 10mg/ml of ground glass in ultra-pure water 
were prepared for quantitative ionic profile using inductively coupled plasma optical 
emission spectrometry ICP-OES (iCAP™ 7000 Plus Series). Solutions were maintained 
at 37 °C for up to 3 days.  Reference standards were used to calibrate the concentrations 
and the amount of each ion was calculated from the linear portion of the generated 
standard curve.  
Preparation of conditioned media. Stock solutions of conditioned media were 
prepared by dissolving glass particles in complete McCoy‟s 5A medium to treat Saos-2 
cells and Clonetics OGM Osteoblast complete growth media to treat osteoblasts. Stock 
solutions were prepared at a concentration of 10mg/ml and left to incubate in a shaker 
incubator at 250rpm at 37 ºC for 24 hours. Following the 24 hour incubation period, 
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stock solutions were filtered using 0.2 micron syringe filter. 3ml of each media was 
taken to record stock solution pH values following glass dissolution. To allow for the 
natural buffering of the body pH neutralisation was completed by preparing conditioned 
media and storing it in humidified atmosphere of 5% CO2/95% air and 37 ºC overnight 
to allow CO2 mediated buffering.       
Cell culture. Human osteosarcoma (Saos-2) cells were purchased from the 
American Tissue Culture Collection and maintained in McCoy‟s 5A medium containing 
1.5mM L-glutamine and 2200mg/L sodium bicarbonate. Media was supplemented with 
1% penicillin, streptomycin and 15% fetal bovine serum (FBS). Primary Normal 
Human Osteoblasts (NHOst) were purchased from Lonza and cultured in Clonetics 
OGM Osteoblast growth media supplemented with 10% FBS, 1% L-glutamine and 1% 
penicillin, streptomycin. Both cell lines were maintained at 37 ºC in a humidified 
atmosphere of 5% CO2/95% air.        
Live/Dead cell viability assay. 10,000 cells per well were seeded of both Saos-2 
and NHOst cells and treated for 72 hours with conditioned media containing the 
dissolution products of 45S5, Ga 1, 2 and 3% at a concentration of 10mg/ml. Following 
the incubation period, a positive control of dead cells was established by incubating 
cells with 70% ethanol for 30 minutes. Cells treated with regular growth media served 
as a negative control. The polyanionic dye calcein-green is retained within live cells, 
producing an intense uniform green fluorescence. Ethidium homodimer-1 (EthD-1) 
enters cells with damaged membranes and undergoes a 40-fold enhancement of 
fluorescence upon binding to nucleic acids, thereby producing a bright red fluorescence 
in dead cells. To stain Saos-2 cells working concentrations of calcein-green at 0.5µM 
and EthD-1 at 2.5µM were combined into one solution and used to treat cells, and to 
treat NHOst cells both calcein-green and EthD-1 were both prepared at a concentration 
of 0.5µM. Cells were overlaid with 100µl of staining solution and left to incubate for 45 
minutes at room temperature. Cells were photographed using a fluorescent microscope 
at 100X magnification.  
 Cell cytotoxicity and proliferation. Cytotoxicity was analysed using MTT 
viability assay (Thermo Fisher), where 5000 cells per well of both Saos-2 and NHOst 
cells were cultured using conditioned media containing 10mg/ml respective glass 
compositions, for a period of 72 hours. 10µM Etoposide was used as a positive control, 
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while cells grown using normal cell media served as a negative control. For the MTT 
assay, a 12mM stock solution of 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium 
bromide (MTT) was prepared as per manufacturer‟s instructions and diluted 1/10 in 
phenol red free media before being added to the cells, which were incubated for 4 hours 
at 37 ºC. Following the incubation 75µl of treatment was removed and 50µl of Dimethyl 
sulfoxide (DMSO) was added and left to incubate at 37 ºC for 10 minutes. 
Metabolically active cells reduce MTT to formazan and after formazan extraction the 
optical density was measured using a spectrophotometer (at 570 nm). This assay was 
performed in quintuplicate. 
Statistical analysis. 
Experiments described above were performed with at least three independent 
samples per data point. Data were analysed using SPSS version 21 and GraphPad Prism 
6. MTT, ICP and pH results are expressed as the mean ± standard deviation. To 
compare cell viability between different time points and glass compositions Two-way 
ANOVA and Tukey‟s multiple comparisons test was conducted to test for significance 
with statistically significant values defined as P < 0.05. Fluorescent microscopy 
and Live/Dead staining was used to distinguish between viable and non-viable cells 
results are qualitative and clearly indicate cell cytotoxicity or lack of. 
RESULTS 
Glasses and hydroxyapatite formation. A series of gallium doped bioactive 
glasses were successfully prepared. 45S5 Bioglass was used as the control glass and 
gallium oxide was incorporated into the remaining bioactive glasses with increasing 
concentrations (1, 2 and 3% Ga2O3). As shown in Figure 1(a) the glasses were 
completely amorphous with no visible signs of Bragg peaks when examined using X-
ray diffraction. A broad peak has previously been reported for Bioglass
10
 and 
corresponds to the calcium silicate
27
. After placing the glasses in a simulated body fluid 
(salt ion solution at 37 °C) for 7 days a visible layer of amorphous calcium phosphate 
/apatite was observed to have formed on the glass surface. X-ray diffraction confirmed 
the surface layer was an amorphous calcium phosphate / poorly defined highly 
substituted apatite
28
 (Figure 1b) which is consistent with results typically observed for 
bioactive glasses
10
. The feature ~ 26° corresponds to the 002 reflection which 
preferentially occurs and has been previously reported for bioactive glasses
29
. The 
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second feature ~ 32° whist still broad (FWHM of 1.5° is significantly narrower that the 
unreacted glass (FWHM 5.4°). This feature is assigned to overlapping 211, 112 and 300 
reflections (Franchini et al.
24
).  No reduction in apatite formation was observed for the 
gallium containing glasses compared to the 45S5 standard. 
 
 (a)        (b) 
Figure 1 (a) X-ray diffraction spectra of the unreacted bioactive glasses, (b) 
XRD spectra of bioactive glasses after exposure to simulated body fluid for 7 days and 
hydroxyapatite is shown for reference. 
ICP analysis of dissolution products. To determine the concentration of ions 
released from the bioactive glasses ICP analysis was conducted.  The concentration of 
gallium ions released in distilled water as a function of time for 10mg/ml solutions are 
given in Figure 2. A rapid release of ions was observed during the first few hours 
followed by a slower more gradual increase in ion concentration.  
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Figure 2. Release of Gallium ions from 45S5, 1, 2 and 3% Ga doped bioactive 
glasses. 
As expected the concentration of gallium ions increases in an approximately 
linear trend with increasing gallium oxide content. At 24 hours the average gallium ion 
concentrations were 7.3, 18.8 and 30.2 ppm for the Ga1%, Ga2% and Ga3% 
respectively. The gallium concentration approximately stabilised after 24 hours and 
minimal increases in concentrations were observed at 48 and 72 hours. The release rate 
of Ca, P and Si is essential for upregulating gene expression
3
. The ion concentrations 
are not significant for altered Ca, P and Si due to the incorporation of gallium oxide into 
the glasses. For example, at 24 hours the concentration of Si is 65, 70, 61 and 67 ppm 
for 45S5, 1%, 2% and 3% respectively. 
Conditioning media and pH neutralisation. During this study experiments 
were performed using indirect methods as direct contact measurements can cause false 
positive results due to the rapid increase in pH in vitro which is not representative of the 
in vivo environment. For example in vitro studies have indicated that bioglass is 
antimicrobial however in vivo studies by Xie et al have shown that this result is a false 
positive since  pH in the body at the site of bioglass implantation cannot increase to the 
level necessary to inhibit bacterial growth
30
. Allan et al and Begum et al have also 
shown that following pH neutralisation bioglass-conditioned media loses it 
antimicrobial efficacy
31,32
. Is it also known that pH fluctuations have the same effect on 
cells, which is why preconditioning is sometimes required for bioactive glasses
33
.  
Furthermore the dissolution products will circulate more widely though the body 
and are therefore more like to prevent metastasis compared to direct contact with the 
bioactive glass. The conditioned media was prepared by adding 10mg/ml of bioactive 
glass to McCoy‟s media and incubating at 37 °C for 24 hours in a shaking incubator. As 
shown in figure 3 the conditioned media shows a significant rise in pH as sodium and 
calcium ions rapidly leach from the glass in the surrounding media. pH readings taken 
directly after conditioning the media are designated as time point 0 in Figure 3. 
Deviations from neutral pH are known to have detrimental effects on cell 
viability/proliferation, furthermore it is known that the body naturally buffers pH. 
Therefore the conditioned media was incubated at 37 ºC in a humidified atmosphere of 
5% CO2 for up to 72 hours to buffer the pH. McCoy‟s media was used as a control and 
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it is clearly evident over the course of 72 hours the pH of the media fluctuates 
marginally from 7.91 at time point 0 to 7.23 at 72 hours, both readings within the 
physiological pH range acceptable for cell growth and maintenance. In contrast 
10mg/ml of 45S5 bio-active glass significantly elevates the pH of the media and at time 
point 0 a reading of 10.3 was recorded and a gradual decline was observed over the 
course of 72 hours (1 hour, 9.4, 2 hours, 8.65, 8 hours 7.85). Conditioned media 
generated by the addition of 10mg/ml of 1, 2 and 3% gallium doped bioactive glass also 
exhibits a similar trend, as a high pH was recorded for each glass composition at time 
point 0 (Ga1%, pH 9.45, Ga2% pH 9.26 and Ga3% pH 9.37). At 24 hours the pH of all 
gallium containing conditioned media had decreased to physiologically acceptable 
levels where cell growth is viable (Ga1%, pH 7.77, Ga2% pH 7.81 and Ga3% pH 7.87). 
Beyond 24 hours negligible changes in pH were observed. Therefore in following 
experiments the media was conditioned for 24 hours and then placed in the incubator 
for 24 hours to neutralise before being used. Neutralising the pH in this way eliminated 
any potential cytotoxic effects of the glass conditioned media due to lethal pH. 
 
 
Figure 3. pH measurements of conditioned media cell treatments taken over the 
course of 72 hours. 
Conditioned media containing respective bioactive-glass at 10mg/ml was 
incubated at 37°C in a humidified atmosphere of 5% CO2/95% air. At timed intervals 
pH readings were recorded. McCoy‟s media was used a negative control.      
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 Live/Dead Staining for cell cytotoxicity. Conditioned media containing 3% 
gallium oxide significantly increases osteosarcoma (tumorous) cell death relative to the 
1% and 2% Ga glasses and 45S5 control as shown in Figure 4. A significant increase in 
dead cells was observed between the 45S5 control glass and the 1% and 2 % Ga glasses 
whilst at 3% all cells appeared dead. In contrast all the glasses including the 3% gallium 
remained non-toxic to primary normal human osteoblast (non-tumorous) cells (Figure 
5).  
 
Figure 4. Fluorescence images of Live/dead staining of HTB-85 Saos-2 cells 
cultured for 72 hours in conditioned media containing bio-active glass after pH 
neutralisation. 5000 cells were seeded and left to attach for 24 hours. Following 
attachment cells were treated with A) Mccoy basal media, B) conditioned media 
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containing 45S5 bioactive glass, C) conditioned media containing 1% gallium, D) 
conditioned media containing 2% gallium, E) conditioned media containing 3% gallium 
and F) 1mM Etoposide treatment as a positive inducer of cell death. All conditioned 
media treatments were prepared at 10mg/ml of the respective glass. Images were taken 
using a fluorescent microscope at 100x magnification.  
 
 
 
 
Figure 5. Fluorescence images of Live/dead staining of NHOst-Osteoblasts 
cultured for 72 hours in conditioned media containing bio-active glass. 5000 cells were 
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seeded and left to attach for 24 hours. Following attachment cells were treated with A) 
OBM basal media, B) conditioned media containing 45S5 bioactive glass, C) 
conditioned media containing 1% gallium, D) conditioned media containing 2% 
gallium, E) conditioned media containing 3% gallium and F) 1mM Etoposide treatment 
as a positive inducer of cell death. All conditioned media treatments were prepared at 
10mg/ml of the respective glass. Images were taken using a fluorescent microscope at 
100x magnification. 
Osteosarcoma and osteoblast cell viability. The cytotoxicity of conditioned 
media containing 1, 2, 3% gallium at 10mg/ml was assessed using the MTT assay on 
both osteosarcoma and osteoblast cells. No significant reduction in Saos-2 cell viability 
was observed between the positive control (unconditioned media) and the gallium free 
control glass (45S5). However a steady but significant decrease in Saos-2 cell viability 
was observed with increasing gallium oxide content in a dose response manner (Ga 2% 
p <0.01 and Ga3% p <0.0001) as shown in Figure 6. After 72 hours in conditioned 3% 
Ga conditioned media Saos-2 cell viability was less than 50%. In contrast conditioned 
media from the glasses showed no cytotoxic effects against osteoblast cells as shown in 
Figure 7. In each experiment 10nm etoposide was used as a positive control and a 
known inducer of cell death (p <0.0001). 
 
Figure 6. SOAS-2 cell viability following treatment with pH neutralised 
conditioned media containing 10mg/ml   bio-active glass compositions over 72 hours.  
SOAS-2 osteosarcoma cell viability was determined following treatment with 
conditioned media containing 10mg/ml 1% Gallium, 2% Gallium, 3% Gallium and 
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compared to 45S5 as a control. 10µM Etoposide was used a positive control (p = 
<0.0001). Two-way ANOVA and Tukey‟s multiple comparisons test was conducted to 
test for significance, data are presented as mean ± SD. Significance was set at p = 
<0.05, N = 4.   
 
 
Figure 7. NHOst cell viability following treatment with conditioned media 
containing 10mg/ml of bio-active glass compositions over 72 hours.  
NHOst osteoblast cell viability was determined following treatment with 
conditioned media containing 10mg/ml 1% Gallium, 2% Gallium, 3% Gallium and 
compared to 45S5 as a control. 10µM Etoposide was used a positive control (p = 
<0.0001). Two-way ANOVA and Tukey‟s multiple comparisons test was conducted to 
test for significance, data are presented as mean ± SD. Significance was set at p = 
<0.05, N = 4.   
DISCUSSION 
Orthopaedic products based on Bioglass
®
 45S5 have been used in a wide range 
of bone regeneration applications. These applications include trauma arthroplasty, spine 
fusion and the general filling of bone defects after cyst or tumour removal
34,35
. In 
essence bioactive glasses are biodegradable controlled release materials. Bioglass 45S5 
provides a controlled release of Ca and P ions which precipitates into hydroxyapatite, 
and through the controlled release of Ca, P and Si gene expressions are upregulated. 
Considerable research effort has been devoted to modifying and enhancing the delivery 
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of ions. For example, cobalt ions have been added to bioactive glasses to enhance 
vascularisation
36,37
 whilst silver ions have been incorporated to enhance the 
antimicrobial properties of bioglass
38
. To date there have been no reports of bioactive 
glasses being tailored specifically for bone cancer applications. Whilst there have been 
alternative bioactive glasses developed for treating deep seated soft tissue cancers
12,13
  
these materials do not work through the controlled dissolution of ions and are in fact 
highly insoluble as they are used to deliver controlled radiotherapy. Consequently this 
class of materials are unable to promote apatite formation or stimulate gene expression, 
in addition it is also difficult for the body to excrete these materials.   
The present study has successfully incorporated gallium ions into bioactive 
glasses to specifically target bone cancer applications. Gallium ions have previously 
been incorporated into bioactive glasses for antimicrobial benefits. However the 
systems previously studied have been fundamentally different. For example the glasses 
developed by Wren and Towler were based on modifying glasses for bone cement 
applications which contained very high concentrations of zinc oxide
20-22
. Consequently 
those glasses are highly insoluble compared to the glasses developed here. The glasses 
developed by Franchini, Lusvardi et al. also found that when gallium oxide was 
incorporated the glasses became less soluble due to the stabilising effect of gallium. It 
took 30 days for glasses with 1.0 and 1.6 mol % to be fully covered in homogenous Ca-
P rich layer.   
The glasses presented in this study show a rapid release of gallium within an 
hour of immersion in SBF. It is envisaged that the release of gallium ions will be 
reduced by the formation of the ACP/apatite layer and that the glasses will dissolve over 
an extended time period provide a long term therapeutic benefit. Gallium-containing 
hydroxyapatite has been previously reported where the substituted apatite can 
accommodate up to 11% Ga ions by mass
39
. In addition gallium is known to 
preferentially locate in bone
40
, it is therefore likely that a significant fraction of the 
released gallium remains localises in the ACP /apatite layers.   
Here through the addition of gallium and by tailoring the silicon content to 
maintain the network connectivity a series of dose dependant release glasses were 
manufactured. Live dead staining and MTT cell viability assays both revealed a 
significant reduction in cell viability for tumorous Saos-2 cells in the presence of 
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bioactive glasses containing gallium. Glasses containing the highest concentration of 
gallium demonstrated the greatest reduction in sarcoma cells. Bioglass doped with 3% 
Ga showed a 50% reduction in viable Saos-2 cells. Gallium containing glasses were 
found to have no detrimental effects on the non-tumorous primary normal human 
osteoblast cells compared to the gallium free glass and control media. Gallium ions are 
known to localise in tumour cells via transferrin receptors
15
. It is noteworthy that 
tumour cells express a significantly higher number of transferrin receptors, relative to 
non-cancerous cell types. Existing literature has elucidated numerous mechanisms 
behind the anti-neoplastic properties of gallium; including altering the three-
dimensional structure of DNA, inhibiting DNA polymerase function and dysregulating 
protein synthesis. Furthermore gallium has been reported to increase cell membrane 
permeability, thereby destabilising electric charges at the surface of the cell and 
inducing an increased efflux of calcium from mitochondria and initiating the 
preliminary steps involved in apoptosis. In addition gallium preferentially locates in 
metabolically active regions where new bone formation and bone remodelling occurs
40
. 
Whilst it is envisaged that these glasses would be used as part of a combined 
therapy, including drug delivery, it is interesting to compare our results directly with 
recently reported controlled drug release calcium phosphates developed for 
osteosarcoma therapy. Recently Hess et al. have assessed the efficacy of calcium 
phosphates doped with cisplatin, doxorubicin (DOX) and co-doped with both drugs
39
. 
The viability of the osteosarcoma cell line MG-63 was assessed after exposure to the 
controlled release calcium phosphates for up to 7 days. For samples where DOX was 
incorporated into the matrix only a 9% kill was reported, Samples with cisplatin beads 
and DOX loaded in the matrix resulted in a 19% kill of MG-63 cells. The composites 
co-doped with both cisplatin and DOX loaded beads exhibited the lowest cell viability 
of 34%
39
. The gallium doped bioactive glasses developed in this work therefore exhibit 
a comparable toxicity to sarcoma cells compared to calcium phosphate scaffolds loaded 
with anti-cancer drugs.  
Whilst this study has been careful to avoid exposing cells to un-physiologically 
relevant pH fluctuations, which are more likely to occur in vitro and could potentially 
lead to unrepresentative results it is worth noting that pH fluctuations caused by these 
bioactive glasses may be potentially beneficial in vivo. For example, human 
osteosarcoma sites can be acidic in nature, the release of sodium and calcium ions from 
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these bioactive glasses will increase the pH and reducing the acidity. This can be 
potentially beneficial in two ways; firstly acidosis of intramedullary extracellular fluid 
can inhibit the proliferation of osteoblasts and secondly raising the pH can prevent 
spontaneous metastases.  
CONCLUSIONS 
In conclusion our data has demonstrated that gallium doped bioactive glasses 
can be designed to selective target bone cancer cell lines, reducing tumorous cell 
viability by over 50%, whilst still promoting normal human osteoblast cell viability and 
proliferation. Hydroxyapatite formation was observed when the glasses were placed in 
simulated body fluid and no reduction in formation was observed for the gallium 
containing glasses compared to the gallium free 45S5 bioglass control. The gallium 
doped bioactive glasses provide a localised controlled delivery of gallium ions at the 
surgical site of interest and has considerable potential clinical applications for bone 
cancer treatment.  
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FINAL CONSIDERATIONS 
The whole set of investigations described in this thesis aimed to elucidate crucial 
aspects of the incorporation of Niobium into the Bioglass®45S5 structure regarding 
bioactive properties such as osteostimulation, osteoinduction, osteoconduction, and 
biocompatibility. We also verified the efficacy of incorporating Gallium into 
biodegradable bioactive glasses to promote death of osteosarcoma cells.  So far, our 
results showed that adding Nb2O5 into Bioglass®45S5 improves its bioactivity and 
stimulates osteogenic differentiation human Embrionic Stem Cells (hESCs) and bone- 
marrow- derived mesenchymal stem cells (BM- derived MSCs). In addition, the 
presence of Nb2O5 does not compromise the biocompatibility of the original glass 
composition.  
Despite of the fact our results indicate that the tested modifications are 
promising for the proposed biomedical applications this study presents some limitations 
that require further investigations. The best approach when it comes to treating large 
bone defects is the use of porous three-dimensional scaffolds, so, further studies should 
aim to develop scaffolds made of Nb-doped bioactive glass. A complete investigation of 
the effects of Ga-doped glass on in vivo models of bone cancer should be performed to 
verify the efficacy in treating cancer as well as to test the biocompatibility of these 
glasses. Another aspect that our experiments could not clarify was the mechanism by 
which Nb-doped glasses enhanced bone formation in some experiments. It might have 
been caused by the glass dissolution products and/or by the effects of the glass surface 
over protein adsorption and cells adhesion and migration. More investigations should 
focus on the chemical and topographical characteristics of Nb- containing glass‟ surface 
in order to determine how it affects the behaviour of multipotent cells like hESCs and 
BM-derived MSCs.  
To conclude, we believe that developing novel biomaterials for bone 
replacement our study will reduce the morbidity and to improve the prognostic of 
millions of victims of fractures. Nonetheless, the knowledge generated by the present 
work comes to improve the comprehension about the interaction between the synthetic 
bone substitutes and the injured bone tissue, clarifying the responses of the body in the 
presence of the Nb or Ga- doped bioactive glasses. Thus, the present study foments the 
literature with relevant information for clinic practise and further investigations. 
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